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Chapter 1
General Introduction
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Introduction
Serous epithelial malignancies constitute the majority of malignant tumours
arising in the upper female genital tract (1). Three tissues are accountable as the
tissue of origin of these malignancies: the Ovarian Surface Epithelium (OSE) (2),
the Tubal inner Surface Epithelium (TSE) (3-6) and the mesothelial lining of the
abdominal cavity (7). These epithelia give rise to respectively serous ovarian-,
Fallopian tube-, and peritoneal- adenocarcinomas, in this thesis further taken
together as serous intraperitoneal carcinomas. Morphology, immunophenotype
as well as clinical behaviour are very similar for these three entities (8-13).
Controversy exists on which tissue is most prone to undergo carcinogenesis.
Difficulties in identification of site of origin at the late stage that these diseases
are usually detected, when ovary, Fallopian tube and abdomen are all involved,
in addition to macroscopical and microscopical resemblance, are the major cause
of this debate (14;15). As a result of the detection at late stage of disease, little is
known on initial steps leading to serous epithelial malignancies.
The most commonly accepted theory regarding serous carcinogenesis, assumes
that OSE cells undergo metaplasia towards a serous phenotype (2). From this state,
some of these cells would accumulate further genetic changes, and also transform
morphologically through the usual hyperplasia-dysplasia-carcinoma sequence
and eventually become serous epithelial malignancies. This theory would mean
that serous premalignant lesions would occur at a certain frequency in cases
with full-blown serous cancers as well as in patients at risk for such cancers.
Females at highest risk for serous intraperitoneal cancer are those with a hereditary
high risk to develop breast / intraperitoneal carcinoma (16). In the majority of
these women, germline mutations in one of two genes have been identified that
predispose for these carcinomas; the BReast CAncer 1 (BRCA1) gene on
chromosome 17q (17) and the BReast CAncer 2 (BRCA2) gene on chromosome
13q (18). Lifetime risk of serous intraperitoneal carcinomas in these women can be
as high as 60% (19;20). To reduce the cancer risk in these women, prophylactic
bilateral salpingo-oophorectomy is advised to women who have completed
their families (21).
The studies reported in this thesis highlight the frequency distribution of
(pre)malignancies in prophylactically removed ovaries and Fallopian tubes in
patients at high hereditary risk of serous intraperitoneal cancer. Moreover, initial
genetic steps leading to serous carcinomas have been studied. The results from
our studies let us propose that in women at hereditary high risk to develop
breast / intraperitoneal carcinoma not OSE, but TSE is most at risk to undergo
carcinogenesis.
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Aims of the thesis
To review the existing literature regarding the cell of origin of serous intraperitoneal
carcinomas and to review initial steps in (hereditary) serous carcinogenesis. This is done
in chapter two.
To assess the incidence of intra-abdominal malignant tumours in BRCA1 and BRCA2
mutation carriers visiting our outpatient clinic for hereditary cancer. The existing literature
is not clear on what histological subtypes of intra-abdominal malignancies are part of the
BRCA1 / BRCA2 mutation cancer spectrum. Therefore a clinic-based study is performed
on the incidence of subtypes of intra-abdominal malignancies in women with a BRCA1-
or BRCA2- gene mutation. Results are described in chapter three and are compared with
the incidence of subtypes of these malignancies in the general Dutch population.
To assess the prevalence of (pre)malignancies in prophylactically removed female
adnexes from women with a hereditary high risk to develop cancers of these organs.
Prophylactically removed Fallopian tubes, chapter four, and ovaries, chapter five, derived
from women with a hereditary high risk to develop female adnexal cancer are screened
for the prevalence of (pre)neoplastic lesions. Results are compared with an age matched
control group. Special attention is paid to the expression of cell cycle related proteins in
the epithelia as there are: Ki67, p27, p53, cyclin D1 and bcl-2.
To identify (dis)similarities between OSE cultures derived from women with and without
a hereditary high risk to develop female adnexal cancer. Results on growth potential and
morphology are compared in chapter six. Moreover, the expression of the BRCA1 and p53
proteins is studied in OSE cultures from women with and without BRCA1 gene mutations
(chapter seven).
Study results are discussed and an alternative hypothesis regarding the aetiology of
(hereditary) serous carcinogenesis is proposed in chapter eight.
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Chapter 2
Intraperitoneal serous adenocarcinoma: a critical
appraisal of three hypotheses on its aetiology.
Jurgen M.J. Piek, Peter Kenemans, René H.M. Verheijen
Department of Obstetrics and Gynaecology, VU University Medical Center,
Amsterdam, The Netherlands
American Journal of Obstetrics and Gynecology; vol. 191: in press
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Abstract
Serous ovarian-, Fallopian tube-, and peritoneal- adenocarcinomas are
remarkably similar, both in their morphology, as well as their clinical behaviour.
Despite extensive clinical and fundamental research, controversy still exists on
the origin of serous female adnexal tumours. Difficulties in identification of site of
origin at late stage of disease at detection, when ovary, Fallopian tube and abdomen
are usually all involved, in addition to their macroscopical and microscopical
resemblance, are major causes of this debate. In three hypotheses, three possible
tissues of origin are proposed: the ovarian surface epithelium, the Fallopian tube
epithelium and the secondary Müllerian system. We searched for all peer reviewed
papers and reviews that examined "serous ovarian carcinoma", "Fallopian tube
carcinoma", "Müllerian system", "ovarian surface epithelium", "tubal epithelium"
and "peritoneal". We included only papers that could give information on the origin
of serous carcinomas. Additional papers were added by examining references of
overview articles in relevant fields. Discussed are the experimental data underlying
these hypotheses. We conclude with an attempt to integrate the three hypotheses
into a comprehensive model of serous intraperitoneal adenocarcinogenesis.
Introduction
Serous adenocarcinomas constitute the majority of malignant tumours arising
from the ovary (1). In addition, their occurrence has also been described in the
Fallopian tube (2), the uterus (3), the cervix (4;5) and on the female peritoneum (6).
Despite both clinical and scientific importance, controversy still exists as to the
tissue of origin of serous adenocarcinomas (7-12). Phenotypic and genotypic
similarities of these tumours (13-18) and difficulties in identification of site of origin
at the late stage of disease at detection, when ovary, Fallopian tube and abdomen
are usually all involved (19;20), are the cause of this debate.
Ovarian carcinoma is the most common cause of death due to gynaecologic
malignancies. Moreover, it is the most common gynaecologic cancer occurring at
an advanced stage and is diagnosed in 1.8% of all women in Western society
(20-22). The serous subtype represents 60 percent of all sporadic malignant
epithelial tumours of the ovary (1). Serous tumours are even more common in
families in which breast-, ovarian-, Fallopian tube- and peritoneal carcinomas
segregate (23-29). In the majority of these families, a germline mutation in
the BReast CAncer 1 or 2 genes can be detected (30).
Three explanations as to the origin of both sporadic and hereditary serous
adenocarcinomas have been put forward. The first one points towards the
Ovarian Surface Epithelium (OSE) as tissue of origin (31). The second possible
origin is the Tubal inner Surface Epithelium (TSE) (=oviduct epithelium) (9;11).
Finally, remnants of the embryologic Müllerian duct, the secondary Müllerian
system, have been put forward as possible tissue of origin (8). Despite the
importance for both therapeutic and scientific reasons, dispute remains on the
24
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to address this issue within the perspective of findings in morphologic, genetic, and
molecular studies.
Review method
To identify relevant papers used in this review, a Pubmed
(http://www.ncbi.nlm.nih.gov/entrez/query.fcgi) search was performed.
We searched for all peer reviewed papers and reviews that examined "serous
ovarian carcinoma", "Fallopian tube carcinoma", "Müllerian system", "ovarian
surface epithelium", "tubal epithelium" and "peritoneal". We included only papers
that could give information on the origin of serous carcinomas. Additional papers
were added by examining references of overview articles in relevant fields.
The purpose of this review is to give an outline of the available literature;
we selected specifically those papers that reported on oncogenesis on basis of
experimental or observational data. However, no selection was made based on
inclusion/exclusion criteria and the quality of individual reports.
Ovarian carcinogenesis hypothesis
Human Ovarian Surface Epithelium
As early as 1872 the Ovarian Surface Epithelium (OSE) has been implicated by
Wells as precursor of serous tumours (32), since embryologically both OSE cells
and cells that form the Müllerian duct, which eventually forms endocervix,
endometrium and Fallopian tube (33;34), are of mesodermal origin. It is thought
that due to the relative uncommitted phenotype of OSE (35) and the common
embryological ancestry of OSE and Müllerian epithelium, metaplasia of OSE can
occur in the direction of a serous (tubal) phenotype, before entering a malignant
state (36;37). Therefore, ovarian carcinomas are, in contrast to other malignant
tumours, more differentiated than their supposed tissue of origin. For example,
they express more specialized epithelial markers than OSE (38). 
OSE consists of 2 types of modified mesothelial cells (39), which are in continuum
with mesothelium covering other abdominal organs. The first type is cuboidal with
abundant microvilli, the second flat squamous with fewer microvilli (40). Some of
these cells possess cilia (41-43). In a high number of normal ovaries, inclusion cysts
are observed. Some of these ovarian inclusion cysts are lined by cells thought to
be derived from OSE, entrapped within the ovarian stroma during the ovulation
process (44). Also, dynamic interaction of OSE and the underlying ovarian stroma,
during which OSE cells infest into the ovarian stroma, is hypothesized to be a cause
of OSE-lined inclusion cysts (45).
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The Ovarian Surface Epithelium serous tumour carcinogenesis
Three hypothesis regarding OSE related serous carcinogenesis have been postulated.
The first one is the incessant ovulation theory by Fathalla (46). Repeated minor
traumata during ovulation to the mesothelium covering the ovaries and repetitive
exposure of OSE to oestrogen rich follicular fluid are held responsible for mitotic
activity of OSE (47), which could lead to accumulation of unrepaired DNA damage,
and eventually malignancy. Indeed, although still disputed (48-51), OSE cells seem
to play a role in the ovulatory process (52;53). Additionally, OSE in inclusion cysts
is constantly hormonally stimulated by oestrogen producing cells, since no
protection against hormones within the ovarian stroma, by the tunica albuginea,
is present (44). Inhibition of the ovulatory process, as seen during pregnancy,
lactation or oral contra conception use, decreases the risk of ovarian carcinoma
(54-58), possibly by inhibiting mitotic activity of OSE and preventing inclusion of
OSE within the ovarian stroma.
Secondly, the gonadotrophin stimulation theory, as postulated by Cramer and
Welch, indicates that excessive gonadotrophin stimulation of OSE directly, and
production of oestrogen indirectly stimulates OSE, which can lead to accumulation
of unrepaired DNA damage, and eventually malignancy (59). In fact, receptors for
gonadotrophin-releasing hormone (GnRH) (60), Follicle Stimulating Hormone
(FSH) (61;62) and Lutheinising Hormone (LH) (62;63) have been identified in
normal OSE. Also, OSE proliferation is stimulated by FSH and LH in vitro
(62;64-66). This gonadotrophin concept is consistent with the observed decreased
risk of ovarian carcinomas in women who ovulate less (54;55;57;67;68).
Since postmenopausal gonadotrophin levels are high, it can also explain why
most ovarian carcinomas arise at later age. Alternatively, ovulation induction by
gonadotrophin agonists, does not increase the risk of ovarian carcinomas (69). 
Thirdly, irritation causing foreign body material, like talcum powder, which
enter the abdominal cavity through the vagina (70-74), has been implicated in OSE
related carcinogenesis (71;75). However, this theory is disputed, since studies
examining genital exposures to potentially carcinogenic compounds, such as dusting
of sanitary napkins with talc, do not show consisted results concerning the risk
of ovarian cancer (76-82).
Human Ovarian Surface Epithelium in vivo studies
It is of interest to study prophylactically removed ovaries from women harbouring
a hereditary high risk to develop female adnexal (ovarian / Fallopian tube)
carcinomas, mainly due to BRCA1 or BRCA2 gene germline mutations, since these
ovaries are expected to bear an increased frequency of premalignant changes.
Table 1 summarizes these studies.
Some of these studies indicated that cortical inclusion cysts, papillomatosis,
cortical invaginations, nuclear enlargement and stromal activity are more often
present in ovaries from women with hereditary predisposition for female adnexal 
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(serous) adenocarcinomas (84;87-90). Other studies contradict these findings
(84-87;91). Three recent studies on the expression of cell cycle and differentiation
related markers in OSE in vivo, indicate no differences between OSE from women
with and without this hereditary predisposition (92-94). Furthermore, proliferative
activity of surface epithelial inclusion cysts is negligible low in normal ovaries (95).
Other studies highlighted the occurrence of occult malignancies within prophylactic
adnexectomies of women at high hereditary risk to develop breast and female
adnexal cancer, as summarized in table 2. 
Nineteen occult malignancies have been reported in a total of 169 reported
prophylactic salpingo-oophorectomies, including seven cases of occult serous ovarian
and 10 cases of occult serous Fallopian tube cancer (89;96-100). Furthermore, three
cases of serous borderline tumours have been described in these series.
Table 1. Statistical significance of phenotypical differences between prophylactically removed
ovaries from women with a hereditary high risk to develp female adnexal (ovarian / tubal)
carcinoma and ovaries from women without such risk (ns = not significant).
Open field = not studied as parmaeter in indicated study.
Piek Casey Barakat Stratton Werness Deligdisch Salazar Gusberg
et al., et al., et al., et al., et al., et al., et al., et al.,
2003 2000 2000 1999 1999 1999 1996 1983
(83) (84) (85) (86) (87) (88) (89) (90)
Inclusion cysts ns ns 0.016 0.006
Papillomatosis 0.039 ns ns ns 0.005
Cortical ns ns ns 0.0004
invaginations
Nuclear ns 0.006 A Nuclear
enlargement distincion enlargement
could be in ovaries of
made twins. None
between in control
normal-, ovaries
dysplastic-
and
neoplastic
nuclei.
Stromal acitivity ns 0.00017
Hyperplasia ns ns ns
Metaplasia ns ns
Pseudo ns
Stratification ns
Psamoma ns
bodies
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Also of interest are studies on contra-lateral ovaries from women with unilateral
ovarian carcinoma. In four studies, in which unaffected ovaries of patients with
unilateral ovarian carcinoma were compared to a control group of ovaries from
women without ovarian tumours, the number of inclusion cysts and the number of
cysts lined by cells with a serous differentiation was increased (45;101-103).
Two other studies revealed a higher frequency of hyperplastic and also serous
metaplastic changes in unaffected ovaries of patients with unilateral ovarian
carcinoma or endometrial carcinomas when compared to a control group (104;105).
In vitro morphological studies of the Ovarian Surface Epithelium
OSE obtained from ovaries of women with a hereditary high risk for developing
female adnexal carcinomas, has been studied in vitro and compared to OSE cultures
derived from women without a hereditary predisposition (106;107). A variety of
pre-malignant defects in these OSE cultures can be expected to be maintained or
even to be specifically expressed under culture conditions (108). Phenotypical
differences have been shown between these groups (table 3).
In culture, predisposed OSE possessed a more stable epithelial character as
defined by keratins 7 and 8 expression (109) and CA125, a marker for Müllerian
differentiation (110), was expressed in a larger fraction of cells (111). However, our 
group recently challenged most of these observations. No differences could be
detected with regard to morphology, ability to grow in culture, and expression of 
Table 2.  Incidence of occult malignancies in prophylactically removed adnexes of women with a
hereditary predisposition for female adnexal (= ovarian / Fallopian tube) cancer
(na = data not shown in original paper)
Author number of Diagnosis of Diagnosis of Diagnosis of Diagnosis of
carcinomas serous other types serous serous tubal
found (%) ovarian of carcinoma peritoneal carcinoma
carcinoma carcinoma
Salazar et al., 2 / 20 (10%) 1 1 na na
1996 (89)
Werness et al., 2 / 20 (10%) 1 1 na na
2000 (96)
Lu et al., 4 / 33 (12%) 2 2 na 0
2000 (97)
Colgan et al., 5 / 60 (8%) 3 0 na 2
2001 (98)
Agoff et al., 6 / na na na 1 5
2002 (99)
Leeper et al., 5 / 30 (17%) 0 1 1 3
2002 (100)
28
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keratins 7 and 8, vimentin, Fibroblast Specific Marker (FSM), collagen type IV,
calretinin and CA125 between female adnexal predisposed and control OSE cultures
(112). Furthermore, hepatocyte growth factor, a regulator of cell growth, motility
and induction of epithelial morphogenesis (115-118) and its receptor c-met
(119;120), both also important in ovarian carcinogenesis (121), are expressed more
stable in predisposed OSE. Finally, E-cadherin expression was observed to be
related to predisposed OSE and not to OSE derived from women without a female
adnexal cancer predisposition (114). This calcium dependent adhesion molecule
(122) is normally not expressed in OSE, but expression is detected in normal serous
epithelium lined inclusion cysts (123;124), indicating activation of the E-cadherin
promoter to be essential for the serous metaplastic process that may precede further
malignant derailment. 
In vitro transfection studies of the Ovarian Surface Epithelium
Firstly, OSE has been immortalized by simian virus 40 (SV40) which disrupts
the Retinoblastoma and p53 pathways (125). These OSE cells were negative for
cytokeratin, and for CA125. After E-cadherin gene transfection into these SV40
transfected OSE cells, expression of E-cadherin and CA125 was detected.
Moreover, these cells regained an epithelial phenotype (123). However, transfection
of E-cadherin negative normal fibroblasts with the E-cadherin gene converts these
cells to the epithelial phenotype as well (126). Secondly, one out of six SV40-
immortalized OSE cell-lines produced an undifferentiated carcinoma when injected
in athymic mice (127). Additionally, SV40-immortalized, E-cadherin-transfected
OSE cells caused poorly differentiated abdominal adenocarcinomas in severe
Table 3. Significant phenotypical differences between predisposed OSE, derived from women at
hereditary high risk to develp female adnexal ( = ovarian / Fallopian tube ) carcinoma and
non-predisposed OSE in culture
Predisposed OSE Non predisposed OSE
epithelio-mesenchymal at late passages (p>3) at early passages (p<3)
conversion (keratin and
collagen III expression vs.
reduced keratin and high
collagen III expression (109)
CA125 expression at first remains relatively high decreased
and later passages (111)
Mean telomeric length in 5000 bases 4000 bases
SV40 immortalized OSE
at p15 (113)
mean population doublings 24.6 43.9
(113)
E-cadherin protein and high low
mRNA expression (114)
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combined immunodeficient (SCID) mice (128). Likewise, one OSE cell-line
transfected with the human papillomavirus type 16 E6/E7 genes produced poorly
differentiated tumours in SCID mice. Thus, transfection studies showed OSE to
be capable of malignant transformation.
Animal models with Ovarian Surface Epithelium
Poultry hens kept hyperovulatory under continuous, long-term photo stimulation
are extremely likely to develop serous ovarian or tubal carcinomas (129-131).
Furthermore, OSE derived from Fisher rats, kept in culture for more than 20
passages, subsequently injected into athymic BALB/c mice, gave rise to tumours
with a morphology of adenocarcinomas (132). Also, introduction of the oncogenes
c-myc, K-RAS or AKT2 into OSE of transgenic mice, deficient for p53, caused
ovarian carcinomas to develop (133). In addition, mice chimeric for SV40 Tag,
which was under the control of Müllerian inhibitory substance type II receptor
promoter developed poorly differentiated ovarian carcinomas (134).
Finally, inhibition of p53 was associated with discordant cellular growth rates
and expression of CA125 in bovine OSE cultures (135). Therefore, animal models
confirm results retrieved by in vitro studies.
Ovarian Surface Epithelium included into the ovarian stroma
Most ovarian carcinomas are thought to originate de novo, in the sense that
the malignant tumour does not arise from a pre-existing benign epithelial ovarian
lesion (136-138). Apart from OSE, the epithelium of cortical inclusion cysts,
Inclusion Cyst Epithelium (ICE), has been suggested as precursor
(9;44;136;137;139-143). Inclusion cysts are found from birth till old age,
however, serous metaplastic changes have only been detected in women after
menarche (144;145). Postmenarchal ICE occasionally expresses E-cadherin,
normally expressed in serous tubal epithelium, but rarely or not in OSE
(123;124;146;147). Moreover, in contrast to OSE overlying the surface, bcl-2 positive
cells often line ovarian inclusion cysts. Recently, we and others demonstrated that
bcl-2 is a differentiation marker, also of serous tubal epithelial cells (148;149).
It is therefore hypothesized that the intra-ovarian hormonal environment in the
fertile phase favours tubal metaplastic changes (35;144;150). In serous ovarian
cystadenomas, both serous and ciliated epithelium coexists in the majority of
tumours.This suggests that ICE is prone to undergo metaplasia towards the
Fallopian tube phenotype (36;37;151). Some studies showed transition from benign
to malignant epithelium in serous cystadenomas (152), signifying the malignant
potential of these metaplastic lesions. Additionally, also male abdominal
mesothelium can undergo metaplasia, since case reports on papillary serous
adenocarcinomas in males have been published (153-155).
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Human Tubal inner Surface Epithelium
The Tubal inner Surface Epithelium (TSE) has been suggested as precursor of
tumours as early as 1847 (156;157). In this year, Doran presented Renauds
drawing of a Fallopian tube adenocarcinoma at a meeting of the Manchester
Pathological Society. However, the first microscopic verification of a serous tubal
adenocarcinoma was noted in 1886 (158).
The three main functions of the Fallopian tube are ovum pick-up, ovum transport,
and facilitation of fertilization. The fimbrial part of the tube is involved in ovum
pick-up and is in close contact with the ovary. In fact, ciliated cells in the tubal
fimbriae facilitate movement of the Fallopian tube across the surface of the ovary
to cover the growing follicle (159-161).
The cellular structure of the TSE reflects its function and varies with segmental
position and hormonal status (162;163). There are 3 basic cells, i.e. ciliated, serous
and intercalary (also regarded as indifferent) cells (43;163-167), which all possess
a wide variety of steroid and other receptors (61;168-172). The ciliated cells are
more abundant near the fimbrial than the uterine end (165) and are tallest at
mid-cycle, when also most mitotic activity is observed in tubal epithelial cells (173),
and undergo progressive shrinkage and deciliation in the 2nd half of the cycle.
Hypertrophy and reciliation occur in the early follicular phase (174). The cell cycle
related protein p21/WAF has been implicated as differentiation marker for ciliated
tubal cells (172), as has LhS28, an antibody against basal bodies of ciliated epithelial
cells (175). The serous cells secrete maximally at mid-cycle and are progressively
exhausted during the secretory phase (174).  Recently, bcl-2 has been described as
differentiation marker for secretory tubal cells (149;172). Finally, both CA125 and
E-cadherin expression are observed in ciliated and serous cells of the Fallopian tube
(176;177). The intercalary cell has been implicated as a stem cell from which mature
epithelial cells regenerate. However, little is known on the exact function of this
cell type (164;166;178).
The Tubal inner Surface Epithelium serous carcinogenesis
Tubal carcinoma is traditionally regarded as a rare entity (179-182), but it has
been argued that its incidence is underestimated due to its presentation at late
stage, causing confusion with ovarian cancer (29;183-185). Most Fallopian tube
carcinomas are of serous histotype (163). Phenotypically, serous tubal
adenocarcinoma resembles ovarian-, cervical- and endometrial serous
adenocarcinomas (13). Only when the criteria by Hu et al.(13), as modified by
Sedlis (186) and Yoonessi (187) are met, the diagnosis of primary Fallopian tube
carcinoma may be made. These criteria require that: a) the main tumour is in the
Fallopian tube and arises from the endosalpinx, b) histological features reflect a
tubal pattern, c) if the tubal wall is involved, the transition between malignant and
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benign tubal epithelium should be detectable, and d) the Fallopian tube contains
more tumour than the ovary or endometrium.
The cause of tubal carcinoma is obscure and only few risk factors are known.
Like ovarian carcinoma, a positive family history, infertility, and low parity have
been incriminated in retrospective studies (186;188-190). In analogy with OSE
(46;54), one explanation is that due to continuous cyclic changes in hormonal levels,
morphologic and mitotic changes will occur more often in TSE of women who
ovulate incessantly (163). During these mitotic and morphologic boosts, DNA
damage can arise. In a retrospective study over 29 years, Stern et al. diagnosed 32
cases of true intraepithelial neoplastic proliferations in Fallopian tubes (191).
Unfortunately, the total number of Fallopian tubes screened in this study was not
mentioned. In yet another study, tubal hyperplasia was detected more often in
tubes from women with serous borderline tumours of the ovary than in women
with either carcinoma of the cervix or the ovary (192). A study on the histological
features of 287 normal Fallopian tube specimens showed epithelial atypia in 7.3%
of all cases (193). Tubal luminal dilatation, plical atrophy and chronic inflammation
were detected in contralateral Fallopian tubes of women with unilateral tubal
carcinoma, indicating that chronic inflammation could be associated with the
development of tubal carcinomas (194).
Recently, we and others showed a high incidence of preneoplastic lesions in
Fallopian tubes that have been prophylactically removed from women harbouring
a hereditary high risk to develop female adnexal carcinomas (195;196).
This contrasts with the ovary, as disagreement exists between studies that
highlighted possible differences between prophylactically removed ovaries from
women harbouring a hereditary high risk to develop female adnexal cancer and
ovaries from women without such risk (84-86;197) (see table 1).
Studies in which women were screened for ovarian carcinomas by CA125 levels,
in order to diagnose disease in early stage, resulted in detection of tubal carcinomas
25 times more often than expected (185;198). Neoplastic lesions in the Fallopian
tube may be expected to be present in up to 8% of patients with serous epithelial
malignancy of the ovary (199). Therefore, the true incidence of tubal carcinoma
is probably highly underestimated. These studies indicate that at present most
Fallopian tube carcinomas are likely to be misdiagnosed as ovarian carcinomas,
since they do not fulfil all the criteria of Hu (13), although they may yet originate
from the Fallopian tube.
Furthermore, due to the widespread practice of prophylactic Bilateral Salpingo
Oophorectomy (pBSO) to reduce the risk of ovarian / Fallopian tube carcinoma
in women harbouring a hereditary high risk to develop female adnexal cancer,
a relatively high number of cases of tubal carcinoma have been revealed
(98-100;189;200-210). Table 4 summarizes these studies. In our study, in which
an assessment was made of tumours arising in women harbouring BRCA1 and
BRCA2 mutations, tubal carcinomas were diagnosed much more frequent than
expected from the general female population (29). As also observed in two women
from our own familial cancer clinic (29), a recent case-report demonstrated
development of a serous Fallopian tube carcinoma in a BRCA1 mutation carrier
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who previously underwent laparascopic oophorectomy, but not salpingectomy (211).
Additionally, growth of Fallopian tube cancer can be extremely rapid in BRCA1
mutation carriers, thus precluding early diagnosis (207). So, evidence accumulates
that TSE is more prone to cancer development than assumed earlier, possibly
even more susceptible than OSE. 
Tubal inner Surface Epithelium in animals
A relative high incidence of serous tubal carcinomas is observed in hens  (212-214)
especially when kept under conditions in which these ovulate daily (129). In 1975
Table 4.  Overview of types of germline BRCA mutation in patients wit  serous Fallopian
tube adenocarcinomas
Author BRCA mutation
Schubert et al., 1997 (200) -BRCA2 3034delAAAc
-BRCA2 3034delAAAc
Tong et al., 1999 (201) -BRCA1 Cys61Gly
Sobol et al., 2000 (202) -BRCA1
-N / A
Rose et al., 2000 (203) -BRCA2 6563delGA
Zweemer et al., 2000 (189) -BRCA1 1410insT
-BRCA1 2804delAA
Hartley et al., 2000 (204) -BRCA1 n/a
Colgan et al., 2001 (98) -BRCA?
Aziz et al., 2001 (206) -BRCA1 185delAG
-BRCA2 2024del5
-BRCA1 5083del19
-BRCA1 C61G
-BRCA1 5382insC
-BRCA1 R1496M
-BRCA2 6174delT
Hébert-Blouin et al., 2002 (207) -BRCA1 K679X
Agoff et al., 2002 (99) -BRCA1 2800delAA
-BRCA1 2800delAA
-BRCA2 2558insA
-N / A
-N / A
Scheuer et al., 2002 (208) -BRCA1 Q563X
Leeper et al., 2002 (100) -BRCA1 2088delAA
-BRCA1 2800delAA
-BRCA2 2558insA
Peyton-Jones et al., 2002 (209) -BRCA2
Baudi et al., 2003 (210) -BRCA2 q3034R
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Ilchmann et al. proposed oviduct epithelium to be the tissue of origin for serous
peritoneal and serous ovarian carcinomas in hens, since all tumours encountered
in their study were of serous histotype and in all cases preneoplastic lesions were
detected in the oviduct (131).
Tubal inner Surface Epithelium included into the ovarian stroma
It has been well documented that many ovarian inclusion cysts are lined by flat to
cuboidal cells, resembling OSE (104). As described before, it has been hypothesized
that OSE-lined cysts develop either during ingrowth of OSE into a stigma, formed
after ovulation (44) or that they are caused by interplay between OSE and the
underlying ovarian stroma (45). However, some of these cysts are lined by cells that
are indistinguishable from epithelial cells lining the Fallopian tube. Moreover, their
morphological arrangement resembles Fallopian tube epithelium architecture
(36;37;44;104;105;144;147;215;216). As described before, it is postulated that these
OSE lined inclusion cysts can undergo Müllerian metaplasia. However, already in
1929 Schiller hypothesized that ovarian carcinomas could also be composed of
ectopic cells. He stated: "This shifting of non-ovarian tissue into the ovary may
occur during fetal time, by developmental error or in adulthood, by either surface
implantation of normal tissue or metastasis of neoplastic tissue" (7;145). In fact,
the fimbrial end of the Fallopian tube closely interacts with the ovarian surface
(161;217). Therefore, it is conceivable that TSE cells are sometimes seeded on the
ovarian surface or onto a formed stigma, and are subsequently included within
the ovarian stroma (9). 
Additionally, during menstruation, retrograde flow through patent Fallopian tubes
occurs carrying endometrial cells (218), but also TSE (9;219). So, besides direct seeding
of TSE cells, retrograde flushed tubal cells could also become indirectly included within
the ovarian stroma, eventually creating serous and ciliated cell lined inclusion cysts (9),
which eventually can develop into malignancy, as we recently identified dysplastic
transformation of an TSE-lined inclusion cyst in one ovary derived from a woman
undergoing pBSO (220). In fact, the stigma wound might be excellent feeder layer
for TSE cells.
In addition to inclusion of TSE into the ovarian stroma, it also has been postulated that,
in analogy with endometriosis (221-225), TSE cells can be spilled onto the peritoneum
and can form endosalpingiotic lesions (226-236), which eventually can cause serous
peritoneal carcinomas, as has been described for endometriosis and endometrioid
adenocarcinoma (237). Like Fallopian tube carcinoma, the incidence of primary serous
peritoneal carcinomas is likely to be underestimated as has been indicated in various
studies (238-241).
Other theories on the origin of endosalpingeotic lesions are that these lesions are
caused by a metaplastic process (230;233-235;242-248) or could be part of the
secondary Müllerian system (8;249-252).
In line with the TSE hypothesis are observations such as the fact that inclusion
cysts in premenarchal ovaries are invariably lined by flat to cuboidal cells and only
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that ovulation is necessary for inclusion cysts to arise. Furthermore, in women who
underwent tubal ligation and / or hysterectomy a decreased risk of ovarian
carcinoma has been observed (253-258). Discontinuity of retrograde menstrual
flow has been hypothesized to cause this reduction (9). Although literature is not
consistent in this perspective, some studies show reduction of endometrioid and/or
clear cell carcinomas after tubal ligation (259). This suggests that tubal ligation is
protective against those neoplasm’s that commonly arise in endometriosis which
is often due to retrograde menstruation.
Also, in a survey of epithelial inclusions within 470 ovaries, 22% showed tubal
inclusions against 5% endometrial inclusions (145). This indicates that the exposure
of the ovarian surface to tubal cells is higher then to endometrial cells, which is
concordant with the female anatomy. This theory also explains the risk for
women from female adnexal-cancer-prone families to develop peritoneal serous
adenocarcinomas after they underwent pBSO (260-262). In vivo evidence
substantiates this exfoliation theory. Ciliary tufts were present in fluid obtained
from the pouch of Douglas. The authors concluded that these structures were the
result of exfoliation of cells from the distal portion of the Fallopian tube (219).
Endosalpingiosis was present in 22% of peritoneal lavage specimens obtained
during prophylactic adnexectomy in women at high risk to develop female adnexal
cancer (263). Moreover, malignant cells were present in two out of five peritoneal
washings of women with family histories of female adnexal cancer whom underwent
a pBSO procedure, and appeared to have occult tubal carcinomas (99).
This indicates that exfoliation of Fallopian tube neoplastic cells may occur at early
stage of disease. It is conceivable that these cells seed onto the ovary and eventually
cause ectopic tumours.
Secondary Müllerian system carcinogenesis hypothesis
Secondary Müllerian system
The secondary Müllerian system (sMs) designates structures lined by Müllerian
epithelium found outside the cervix, uterus and Fallopian tubes (264;265).
There are very few data on the origin of the sMs. However, remnants of the proximal
portion of the Müllerian ducts (paramesonephric duct) have been implicated
(8;246). For the purpose of this review, the sMs is considered such an embryologic
remnant. The distal portions of the two Müllerian ducts fuse in the midline during
embryogenesis, thus giving rise to the superior vagina, cervix, and uterus.
More proximally, the ducts remain separated and become right and left Fallopian
tube (33). It is hypothesized that the most proximal portions of each Müllerian
duct do not develop further but regress leaving remnants, e.g. the hydatid of
Morgagni, which are cysts that lie adjacent to the Fallopian tube and are lined by
cells with a similar morphology as TSE (33). Some authors also consider
endosalpingiosis to be part of the sMs (8;249-252)
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During fetal development, before the secretion of Müllerian Inhibiting Factor
(MIF) by the fetal testes, the Müllerian ducts also develop in male foetuses.
MIF subsequently inhibits their development and invokes a degeneration of the
ducts, leaving at least some Müllerian duct remnants near the testes (33),
but probably also in the abdominal cavity.
Serous (tumour) cells in the secondary Müllerian system
Serous cell lined sMs cysts have been described (8;248;251;266;267) and serous
epithelial tumours have been observed to arise from these sMs cysts in humans
(268-271) and in some animal strains (267;272-275). Furthermore serous cell lined
sMs cysts were detected in a male monkey (276). Additionally, serous tumours
have also been reported to develop in males (153-155;277) and in females after
pBSO for a strong positive family history of breast / female adnexal carcinomas
(260-262;278). Moreover, a case report, showed the occurrence of a separate serous
ovarian and peritoneal carcinoma in one patient (279). These observations indicate
that the epithelial cells which form the lining of the sMs are prone to undergo
transformation into serous carcinomas.
Not fulfilling the criteria of the sMs, although also capable of serous tumour
formation are epithelial cells that line the rete ovarii (267). Some authors speculate
that some retiform tumours could be misdiagnosed as primary serous ovarian
carcinomas (280;281).
Serous carcinogenesis: parallel or integrated pathways?
In this article three possible tissues of origin of malignancies of serous epithelial
tumours in the female pelvis have been described, the Ovarian Surface Epithelium,
the Tubal inner Surface Epithelium and the epithelium of the secondary Müllerian
system. Debate is ongoing which hypothesis is more likely (8-10). However, these
possibilities do not necessarily rule each other out. 
Figure 1 attempts to depict possible routes of serous carcinogenesis. 
Firstly, in this review it has been shown that OSE is capable of malignant
transformation (132;133). Before malignant transformation, OSE probably has
to undergo metaplastic changes towards serous epithelial characteristics. If OSE
would derail into malignancy without first becoming metaplastic, mesotheliomas
would occur. Because of the similarities between serous adenocarcinomas and
mesotheliomas (72;246;282;283), some mesotheliomas are likely to be
misdiagnosed as serous (ovarian) adenocarcinomas.
Secondly, recent insights show TSE to be more prone to develop cancer  than
previously thought (29;185;284), especially in women with a hereditary high risk
to develop breast / female adnexal carcinoma (29;189;195). Since TSE has been
studied only scantly, it is important to study phenotypic characteristics of these
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cells in vitro. TSE cells can easily get entrapped within the ovarian stroma (9),
warranting to study this process in in vivo models. Animals, like the domestic hen,
might prove to be a suitable model. Furthermore, CGH and expression - array
analysis on dysplastic lesions detected in Fallopian tubes of women predisposed
to develop breast / female adnexal carcinoma (195) might reveal genes that are
important in serous tubal carcinogenesis. It is pivotal to study the true incidence
of Fallopian tube carcinomas and to compare phenotype and genotype of these
tumours with serous ovarian-, and sMs carcinomas. This might reveal differences
between true ovarian, true sMs and true Fallopian tube carcinomas (285), or rather
show that they are very similar. It has already been shown that frequency and
pattern of chromosomal changes detected in tubal carcinoma were strikingly similar
to those observed in a heterogeneous serous ovarian adenocarcinoma group (18).
Again, array techniques will allow us to study gene expression profiles between
these entities.
Thirdly, sMs carcinogenesis is pointed out in figure 1. As all human epithelia are
capable to develop into malignancies, this also accounts for (aberrantly situated)
serous Müllerian epithelia. It is also conceivable that these tumours, when detected
at late stage of disease, are diagnosed as primary ovarian carcinomas. 
Finally, in order to verify all findings discussed in this review, we urge that
pathological sampling of both prophylactically removed female adnexes and
adnexes removed for other reasons should be standardised. Both Fallopian tubes
should be transversally lamellated, at least one lamel should be frozen, and the
remainder completely paraffin embedded. The ovaries should be divided into 4
Figure 1.  Scheme depicting the three possible origins of intraperitoneal carcinomas.
ICE = Inclusion Cyst Epithelium
Tubal Inner Surface
Epithelium
Ovarian Surface
Epithelium
ovarian/abdominal paratubal tubal ICE
dysplasia dysplasia dysplasia dysplasia
Seconday Müllerian
System
serous tubal
carcinoma
serous peritoneal
carcinoma
serous ovarian
carcinoma
inclusioninclusion
exfoliation
metaplasia
metaplasia
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longitudinal pieces, one part should be frozen, and the others paraffin embedded.
This will allow genetic research with for example array CGH (286) and expression
arrays on large sample sizes by cooperation of different centres. 
In conclusion: there are probably three distinct types of "serous adnexal
adenocarcinomas". These phenotypically highly similar histotypes may originate
from different tissue types: the OSE, the TSE and the sMs. The frequency
distribution between these three different tissues of origin has to be established,
but tubal origin of intraperitoneal serous carcinomas is probably much more
frequent than currently assumed.
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Addendum 1 to chapter 2
Serous ovarian carcinomas are of tubal origin
Jurgen M.J. Piek (1), Paul J. van Diest (2),
Ronald P. Zweemer (1), Peter Kenemans (1),
René H.M. Verheijen (1).
Departments of Obstetrics and Gynaecology (1) and Pathology (2),
Vrije Universiteit Medical Center, Amsterdam, The Netherlands.
Lancet 2001; 358:844-5
C
h
ap
te
r
2 
 
A
d
d
en
d
u
m
 1
60
S
er
ou
s 
ov
ar
ia
n 
ca
rc
in
om
as
 a
re
 o
f 
tu
ba
l o
rig
in
61
Sir, Steven Narod and colleagues advocate tubal ligation instead of ovariectomy
to  reduce the risk of ovarian cancer in women with a germline BRCA1 mutation (1).
Hereditary epithelial ovarian cancers are almost exclusively of a serous histotype,
a feature also typical of fallopian-tube carcinoma. We have reported that tubal
cancer is part of the cancer spectrum of BRCA1 mutation carriers (2) and we have
noted a high prevalence of dysplastic changes in prophylactically removed fallopian
tubes of women with a hereditary predisposition for ovarian cancer.
Tubal cancer is difficult to differentiate from serous ovarian carcinoma, and is
frequently misclassified as ovarian cancer (3). In 1999, Dubeau postulated that
ovarian serous adenocarcinoma might actually derive from the fallopian-tube
epithelium and not from the ovarian surface epithelium, from which it is commonly
believed to originate (4). Analogous to endometriotic lesions, which can arise from
endometrial cells seeded on to the abdominal cavity and from which endometrioid
adenocarcinoma can originate (5), we believe that tubal cells can also be spilled
and grafted on organs in the abdominal cavity, such as the ovaries.
Our experience shows that tubal epithelial cells can be easily obtained for culture
purposes by flushing the fallopian tube. In view of these observations, we believe
the origin of serous ovarian adenocarcinomas should be reconsidered, since they
may be tubal.
Tubal ligation, as suggested by Narod and colleagues might, therefore, contribute
only partly to a lowered incidence of serous adnexal carcinomas. Since ampullar
tubal epithelial cells still have access to the abdominal cavity, tubal ligation alone
cannot be deemed adequate prophylaxis. We believe the removal of the tube in
addition to the ovary is warranted to provide adequate prophylaxis.
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Authors reply
Sir, Jurgen Piek and colleagues present new theories for the protective effect of
tubal ligation on ovarian cancer among BRCA1 carriers. One or more malignant
cells might be transported along the tube and lodge on the ovarian surface,
presenting later as ovarian cancer, or on the peritoneal surface, presenting as
primary peritoneal cancer. This interesting hypothesis can account for some of
the observations, but not for all. 
We have reported that a high proportion of primary cancers of the fallopian tube
arise in carriers of BRCA mutations (1); the proportion (16%) is actually higher
than the estimates for ovarian or breast cancer. The proportion of carcinomas in
BRCA1 carriers that are assigned as fallopian seems to be higher for small cancers
discovered at prophylactic surgery than for larger cancers that present in
symptomatic women. Advanced lesions with multifocal involvement are likely to
be assigned an ovarian origin by the pathologist. We reviewed 60 samples from
patients undergoing prophylactic oophorectomy (2). Five occult cases of malignant
disease were noted in 39 BRCA1 carriers. The number of malignant foci ranged
from one to seven. In four women the tube was involved, and in only three the ovary
was involved. Two women had tubal involvement only. These studies support the
proposition of Piek and colleagues, that a high proportion (perhaps most) of ovarian
cancers in BRCA1 carriers arise in the fallopian tube.
This theory is consistent with the observation that the risk of peritoneal cancer after
oophorectomy is high in carriers, and that serous papillary peritoneal, fallopian,
and ovarian cancers are indistinguishable on histological examination. If the theory
is correct, tubal ligation, but not oophorectomy, should protect against primary
peritoneal cancers in carriers.
This theory does not explain, however, why the protective effect of tubal ligation
should be restricted to BRCA1 carriers. Also, tubal ligation is highly protective in
the general population (3), but primary peritoneal cancer is much less represented
in non-carriers. The theory is also at odds with increasing evidence that a
substantial proportion of ovarian cancers arise in inclusion cysts. Further studies
on the epidemiology of fallopian cancer, and on the prevalence of premalignant
and molecular genetic changes in the tubes of high-risk women are warranted. 
I recommend that tubal ligation and oophorectomy should be used in combination
to provide the maximum protective effect for BRCA1 carriers and care should be
taken that the fallopian tubes be removed completely at oophorectomy.
Steven Narod
Centre for Research on Women’s Health, Univerity of Toronto, Room 750,
Ontario M5G 1NB, Canada.
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Addendum 2 to Chapter 2
BRCA1 / 2 related ovarian cancers are of tubal origin,
a hypothesis.
Jurgen M.J. Piek (1), René H.M. Verheijen (1),
Peter Kenemans (1), Leon F. Massuger (2), Hans Bulten (3),
Paul J. van Diest (4)
Departments of Obstetrics and Gynecology (1) and Pathology (4), VU University
medical center, Amsterdam. Department of Obstetrics and Gynaecology (2) and
Pathology (3), UMCN st. Radboud, Nijmegen, The Netherlands.
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To the Editor,
We read with interest the research article by Leeper et al. reporting on pathologic
findings in prophylactic oophorectomy specimens obtained from women at high-risk
to develop breast/ovarian carcinoma (1). In this study, occult Fallopian tube cancer
was present in 10% of 30 women harboring a genetically determined high risk.
No ovarian carcinomas (in situ) were diagnosed.
We recently reported on our ongoing study on (pre) neoplastic lesions within
prophylactically removed Fallopian tubes, in which we showed dysplastic (defined as
multilayered epithelium with nuclear hyperchromasia and/or atypia, and increased
proliferation) areas to be present in 50% percent of all patients (2). We have
increased our sample size.
In a cohort of Fallopian tubes from 44 women, 37% of the women harbored truly
dysplastic lesions. Furthermore, we examined ovaries from 87 women at high
hereditary risk to develop breast/ovarian/Fallopian tube carcinoma and compared
findings to those in a control group of women without this risk (n=12). In the
hereditary high risk group, one woman harbored an serous ovarian carcinoma in
situ (CIS), which arose from an inclusion cyst. In 36% of the high risk cases and
27% of controls, like in the CIS case, these ovarian inclusion cysts were lined by
epithelial cells not only of the serous cell type, but also ciliated cells, which are the
2 cell types that normally line the Fallopian tube.
Since the tubal fimbriae facilitate movement of the Fallopian tube across the surface
of the ovary to cover the growing follicle (3;4), and Fallopian tube epithelial cells
can easily be spilled  onto this surface (5), we postulate that most (hereditary)
serous carcinomas do originate from Fallopian tube epithelium and not from the
Ovarian Surface Epithelium. 
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Chapter 3
Histopathological characteristics of BRCA1- and BRCA2-
associated intraperitoneal cancer, a clinic based study
Jurgen M. J. Piek (1), Bas Torrenga (1,2), Brenda Hermsen (1),
René H. M. Verheijen (1), Ronald P. Zweemer (1),
Johan J. P. Gille (2), Peter Kenemans (1), Paul J. van Diest (3)
and Fred H. Menko (2)
(1) Department of Obstetrics and Gynaecology,
(2) Department of Clinical Genetics and Human Genetics and
(3) Department of Pathology, VU University Medical Center, Amsterdam,
The Netherlands
Familial Cancer 2003; 2: 73-8
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Abstract
The aim of the research was to assess possible histopathological differences between
BRCA1- and BRCA2-associated malignant intraperitoneal (ovarian/fallopian
tube/peritoneal) tumors and their sporadic counterparts.
Dutch families harboring pathogenic BRCA1 or BRCA2 mutations were selected.
Included were patients who had had malignant primary ovarian, fallopian tube or
peritoneal tumors. Histopathological data was compared with data obtained from
the Dutch cancer registry between 1989 and 1993 (reference group).
A total of 63 patients with primary intraperitoneal malignant tumors were
identified in 41 families. Non-epithelial malignant tumors were not observed in
the study group versus 6% (n = 404) in the reference group (n = 6,789, P = 0.04).
These tumors were excluded from further analysis, as were ovarian adenocarcinomas
not otherwise specified, since these were detected in 22% of the study group, and in
19% of the reference group (P = 0.76). Serous carcinomas were detected in 94%
(47/50) of the women in the study group in contrast to 62% (3,145/5,088) of the
reference group (P < 0.01). In the study group, mucinous and endometrioid ovarian
adenocarcinomas and serous ovarian borderline tumors each comprised 2.0%
of the tumors. Clear-cell ovarian carcinomas were not detected. In contrast, these
percentages were 16% (P < 0.01), 10% (P = 0.07), 7% (P = 0.16) and 5% (P = 0.12),
respectively, in the reference group. In the study group, 6.0% of the carcinomas
arose in the fallopian tube versus 1.9% in the reference group (P = 0.03).
Four percent of the study group developed primary serous peritoneal carcinomas,
versus six percent in the reference group (P = 0.57).
Serous carcinoma is the predominant type of intraperitoneal malignancy occurring
in women harboring BRCA1 or BRCA2 mutations. Non-epithelial cancer does not
seem to be part of the tumor spectrum of BRCA mutation carriers. This suggests,
therefore, that serous tumors may be the only subtype related to a BRCA1 or BRCA2
mutation. Furthermore, fallopian tube carcinoma occurred more often in BRCA
mutation carriers than in the reference population.
Introduction
In 5–10% of cases, ovarian and fallopian tube (subsequently referred to as female
adnexal) carcinomas are caused by a germline mutation of the BRCA1 or BRCA2
gene (1, 2). Malignant primary peritoneal tumors are also thought to be part of the
BRCA1 or BRCA2 gene mutation cancer spectrum (3, 4). Histologically, these
hereditary tumors are malignant epithelial tumors of various subtypes (5–12).
Clinical diagnosis of hereditary breast/female adnexal cancer is based on a
family  history positive for ovarian, tubal, peritoneal and/or breast malignancy.
However, it is sometimes difficult to obtain medical information relating to relatives,
and, more importantly, hereditary female adnexal cancer may present as sporadic
disease without close relatives being affected (10, 13). For diagnostic purposes,
it is therefore important to evaluate possible histopathological differences between
76
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BRCA1- and BRCA2-associated tumors and their non-hereditary counterparts,
as the presence or absence of certain histotypes may be indicative of the
mutation status of the patient. In view of differential clinical behavior of hereditary
tumors in comparison with sporadic ovarian carcinoma one might expect a difference
in histology (14). 
At present, at our family cancer clinic we have seen 41 families with a proven
pathogenic BRCA1 or BRCA2 mutation in which one or more malignant female
adnexal or peritoneal tumors have occurred. The aim of the present study was
to evaluate the histopathological features of these tumors, to compare our data
with a general population-based reference group and to consider the clinical
implications of our findings.
Patients and methods
At the Family Cancer Clinic of the VU University Medical Center, over 800
families have been counselled regarding their familial predisposition to breast,
female adnexal and peritoneal cancer. We selected those families investigated
between 1992 and 2002 in which germline mutation analysis had revealed a
pathogenic BRCA1 or BRCA2 mutation. The methods used for mutation analysis
have been described previously (14). Pedigree studies and DNA analysis of some
of the family members were performed outside our clinic. From mutation-positive
families we included patients who had had malignant primary female adnexal
cancer or primary peritoneal cancer. Data were collected on clinical characteristics,
including age at diagnosis, histological subtype of tumor, FIGO stage at diagnosis
and (synchronous or metachronous) occurrence of breast cancer. When tumor
material was available, the histological diagnoses were reviewed. The distribution
of histological subtypes found was compared with similar data obtained from the
Dutch population-based cancer registry (The Netherlands Cancer Registry) (15)
(and Dr O. Visser, IKCA, personal communication). This design was chosen because
we wanted to compare the results of two populations, one with a high risk of
intra-abdominal malignancies and one with an average risk. Statistical analysis
was performed using the chi-square and sign tests.
Results
We have counselled over 800 families with a predisposition for breast and/or female
adnexal and/or peritoneal cancer. Two hundred twenty families were eligible for
BRCA1 and BRCA2 mutation screening. Pathogenic BRCA1 or BRCA2 mutations
were demonstrated in 62 of these families. In one family, both a pathogenic BRCA1
and a pathogenic BRCA2 mutation were detected. Of these 64 mutations, 51 were
detected in the BRCA1 and 13 in the BRCA2 gene. Forty-one of these families with
pathogenic BRCA mutations, thirty in BRCA1 and eleven in BRCA2, had one or
more family members with malignant female adnexal or peritoneal tumors. A total
of 63 patients with female adnexal or peritoneal cancers were identified within these
41 families. The main characteristics of these patients are listed in Table 1. 
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Table 1. Summary of clinical characteristics of female adnexal and peritoneal tumors* in 62 patients
from 42 Families with BRCA1 or BRCA2 germline mutations
Id. of family BRCA mutationa Mutation Age at Histological FIGO Basis for Breast Remarks
status # diagnosis subtype§ stage diagnosiso cancer**
(years)
BRCA1 mutation
B010 185delAG C 47 S III PA+ B47
B123 185delAG C 49 Ad III MR
B244 185delAG P 77 Ad IC MR
C 60 PP IIIC PA
B050 1136insA
P 59 S - PA B38/B50
C 46 S IIIC PA+
P 31 S IIIC PA
B060 1240delC C 58 S III PA+
P 46 Ad III PA
B064 1406insA P 54 Ad - MR ##
B032 1411insT O 70 S IIIC PA+ B50
C 41 S III PA+
B101 1411insT P 51 S IIIC PA
C 50 PT IIA PA+ b
B323 2312del5 P 42 Ad - MR
B002 2457C>T(Q780X)
P 70 S - PA+
P 51 S III PA+
O 57 S III PA+
C 64 PP IIIC PA B40
B524 2457C>T(Q780X) P 35 E - PA
B006 2804delAA
O 41 Ad IV PA
C 47 S IIC PA+
C 52 S III PA+ B52
B125 2804delAA C 61 PT - PA+ b
B156 2804delAA P 54 S III PA B44
B189 2804delAA P 62 S - PA
O 60 S III PA
B202 2804delAA P 69 S MR
P 40 Ad MR B65
B223 2804delAA
P 46 Ad - MR
C 57 S IIIC PA+
P 47 S IIB PA+
B664 2804delAA C 50 S IIC PA B48
B029 2809insA P 65 Ad - PA
B004 2841G>T(E908X) P 67 S IIA PA
C 48 S IIIC PA
B834 3604delA C 55 S IV PA
B422 3668AG>T C 55 S III PA
B037 IVS21-36del510& P 63 S - MR
(2)3681insT
B015 3937insG C 47 S IV PA+ B44
B117 3938insG C 48 S IIIC PA+ B42
B027 IVS21-36del510 P 60 S - PA+
P 45 M II PA+ B45
B106 IVS21-36del510 P 54 S - PA+ B53
B107 IVS21-36del510
O 41 Ad IIIC MR
O 42 Ad III MR
O 37 Ad III MR
B353 IVS21-36del510 O 51 PT IV PA+
B495 IVS20+1G>A C 53 S III PA+
B114 5382insC P 49 S III PA
P 61 S IIIB PA+
table continued on next page
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In the remaining 20 families, breast cancer and other carcinomas, but no
intra-abdominal malignancies, were observed. 
The data from the reference group were obtained from the Dutch cancer registry
in which data from the entire Dutch population on invasive tumors of both the
ovary and fallopian tube are included. In total, 6022 primary epithelial malignant
tumors, 404 non-epithelial malignant tumors and 363 serous borderline tumors
were detected between 1989 and 1993 (12).
In our study group, age at diagnosis was 52.4 years (range 31–77 years) for
BRCA1-associated female adnexal tumors and 60.3 years (range 52–71 years) for
BRCA2-associated tumors. The age at diagnosis for The Netherlands Cancer Registry
was 62 years (range 14–98 years) (age BRCA1 vs control group P < 0.001, age
BRCA2 vs control group P = 0.581, age BRCA1 vs BRCA2 P = 0.04).
Table 2 summarizes histopathological data for the study and reference groups.
Non-epithelial malignant female adnexal tumors did not occur in the study group
versus 404 times in the reference group (n = 6,789, P = 0.04). We did not use
these data in further calculations. Adenocarcinomas not otherwise specified were
detected in 22% (14/64) of the BRCA-mutated women and in 20% (1,297/6,385) of 
Table 1. Summary of Clinical Characteristics of female adnexal and peritoneal tumors* in 62 Patients
from 42 Families with BRCA1 or BRCA2 germline mutations
Id. of family BRCA mutationa Mutation Age at Histological FIGO Basis for Breast Remarks
status # diagnosis subtype§ stage diagnosis cancer**
(years)
BRCA2 mutation
B167 1538del14 P 52 S - MR
B037 3864insT& P 63 S - MR
(1)IVS21-36del510
B456 3821delA P 65 S III PA B71
B231 5382insC C 60 S IIIC PA+ ##
B489 5382insC C 55 Ad - PA+
B084 5805del4 C 53 S III PA+
B318 6085G>T(E1953X) P 71 S - PA+ ##
C 55 BO - PA B35
B016 6147delT P 61 S - PA
B373 6174delT O 65 S III PA+
B436 6580delGT C 70 S IIIb PA B66
B145 7647delTG P 56 S III PA B56
C 58 S III PA+
*Ovarian tumor:epithelial ovarian cancer, borderline ovarian tumor, primary Fallopian tube cancer or primary
peritoneal cancer; aBRCA1 (1) or BRCA2 (2) mutation; # Mutation status: C=carrier, O=obligate carrier,
P=probable carrier; § Subtype: S= serous / papillary, M= mucinous, E= endometrioid, Ad: Adenocarcinoma
and other unspecified cancers; BO= borderline tumor, PT= primary Fallopian tube cancer; PP= primary
peritoneal cancer; o Basis for diagnosis: MR= medical report, PA: pathology report (a + sign denotes
histological review); ** Breast cancer: synchronous or metachronous breast cancer and age at diagnosis
(yrs); ##: peritonitis carcinomatosa, probably primary ovarian cancer; bdescribed previously by Zweemer
et al., 2000 (Family 2 and 1, respectively).
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the reference group (P = 0.76). When these patients were also excluded from further
calculations, serous intraperitoneal carcinomas were detected in 94% (47/50)
women in the study group in contrast to 62% (3,145/5,088) of the reference group
(P < 0.01). Serous ovarian carcinomas were detected in 84% (42/50) women in
the study group versus 54% (2,750/5,088) in the reference group (P < 0.01).
One mucinous ovarian tumor (2.0%) was detected in the study group versus 16%
(829/5,088) of the reference group (P < 0.01). Endometrioid ovarian carcinoma
was detected in one (2.0%) woman from the study group versus 10% (517/5,088)
of the reference group (P = 0.06). No clear cell ovarian carcinomas were detected
in the study group versus 5% (234/5,088) of the reference group (P = 0.12).
Of all 50 cancers in the study group, 3 (6.0%) originated from the fallopian tube
versus 95 (1.9%) from the reference group (P = 0.03). In the study group, 1 (2.0%)
woman developed a serous borderline tumor of the ovary versus 363 (7.1%) in
the reference group (P = 0.16). Of these women, 2 (4.0%) developed primary serous
peritoneal carcinoma versus 300 (5.9%) in the reference group (P = 0.57).
Discussion
The histopathological features of female adnexal and peritoneal tumors in families
in which a pathogenic BRCA1 or BRCA2 mutation had been detected were studied to
obtain an optimally defined study group. We compared our results with data
obtained from the general Dutch population-based reference group. In a comparable
percentage of cases and reference tumors, even after reviewing (which was available
Table 2. Histological Subtypes of Female Adnexal and Peritoneal Cancers
Epithelial Ovarian Cancer Study Group Reference Group
Number (%) Number (%)
Serous 42 (84%) 2750 (50.1%)
Mucinous 1 (2.0%) 829 (15.1%)
Endometrioid 1 (2.0%) 517 (9.4%)
Clear cell 0 (0%) 234 (4.3%)
Adenocarcinoma, not specified 14‡ 1297°‡
Serous borderline tumor 1 (2.0%) 363 (6.6%)
Epithelial Tubal Cancer
Serous 3 (6.0%) 86 (1.6%)
Mixed 0 (0%) 9 (0.1%)
Epithelial Peritoneal Cancer
Serous 2 (4.0%) 300 (5.5%)
Non-Epithelial and Stromal Cell 0 (0%) 404 (7.3%)
Malignancies
* Epithelial ovarian cancer in the Netherlands, 1989-1993 (Visser, O. et al., 1997); o: includes other
adenocarcinomas (1184) and other carcinomas (113), ‡ : not applied in calculations (see text).
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in 44% of the cases), no histological subtype could be determined. These tumors
were therefore classified as non-specified adenocarcinomas. Of the remaining cases,
it was clear that almost all cancers were of the serous type, in contrast to the
reference group. Clear-cell cancers as well as non-epithelial tumors did not occur
among BRCA mutation carriers and mucinous and endometrioid cancers were rare.
In the studies of Boyd et al. (8), Werness et al. (16) and Risch et al. (10), a total
of more than 200 BRCA-mutation related tumors were described. No mucinous
tumors were detected, although most BRCA1-related tumors are detected at a young
age, when a relatively high percentage of the general female population is likely to
have mucinous tumors (15). In these studies, 21 (10%) endometrioid and 5 (2.4%)
clear-cell tumors were also diagnosed. The question arises whether the latter cases
are really caused by the BRCA mutation. It cannot be excluded that they may in
fact be ‘sporadic’, since BRCA mutation carriers have the same baseline risk of
non-BRCA-related cancers as the general population. Serous cancer may be the
only tumor type truly caused by BRCA1 or BRCA2 mutations, as suggested in a recent
study by Shaw et al. (11).
In our study group, one patient had a serous borderline tumor. Borderline tumors
in hereditary breast/female adnexal cancer families have generally been regarded as
coincidental findings (10, 12). However, this is now being questioned. There have
been six reported cases of borderline tumors in a BRCA gene mutation carrier, one
of which has been described by Piura et al. (17). These authors propose that ovarian
serous borderline tumors, including the subform of non-invasive micro-papillary
serous carcinomas, should be considered related to BRCA gene germline mutations.
However, we only detected one (2%) borderline tumor, whereas in the reference
group 7% were borderline tumors. Our data does not therefore support this theory.
In our cases of mucinous, endometrioid and borderline ovarian tumors, molecular
studies may show whether the underlying BRCA mutation can be considered to be
a causative factor. 
Primary cancer of the fallopian tube is one of the possible clinical manifestations
in BRCA carriers (2, 18, 19). In our cohort of 50 patients, 3 (6.0%) had this type of
cancer. In contrast, fallopian tube carcinoma only comprised 1.9% of all female
adnexal tumors in the Netherlands Cancer Registry. Furthermore, it is likely that
a subset of tumors diagnosed as primary serous ovarian carcinomas actually
represent fallopian tube carcinomas, as has previously been suggested (20, 21).
This is based on the following observations: (1) serous ovarian and fallopian tube
carcinoma are phenotypically indistinguishable (2, 22), (2) most serous tumors in
our cohort were stage III, when fallopian tubes are usually involved, and (3) only
when the tumor bulk is in the fallopian tube is a diagnosis of fallopian tube
carcinoma made (23–26). Therefore, one of the implications of this study is that
the fallopian tubes should be removed at prophylactic oophorectomy (25).
Primary peritoneal cancer might also be part of the BRCA1- and BRCA2-related
cancer spectrum (3, 4, 27). Both women in our cohort who developed this type
of tumor had undergone prophylactic oophorectomy; however, the fallopian tubes
remained in situ. It should be noted that metastasized fallopian tube cancer
may mimic primary peritoneal cancer, so a primary fallopian tube origin cannot
be excluded in these cases.
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Most family members in our study group harboured BRCA1 mutations. Age at
diagnosis of BRCA1-associated ovarian cancer is reportedly younger than for
sporadic disease, whereas BRCA2-associated ovarian cancer does not differ
significantly from age at diagnosis of sporadic disease (10). Similar results were
obtained in this study.
Synchronous or metachronous breast cancer was encountered in 16 (25%) patients
from the study group, 12 in BRCA1 and 4 in BRCA2 mutation carriers. In all but
two patients (see Table 1) the breast cancer preceded or presented simultaneously
with the intraperitoneal cancer. The occurrence of double tumors is obviously one
of the manifestations of hereditary susceptibility for these cancers.
In conclusion, serous carcinoma is the predominant type of intraperitoneal
malignancy encounterered in women harboring BRCA1 or BRCA2 mutations.
Nonepithelial cancer does not seem to be part of the tumor spectrum of BRCA
mutation carriers. It is possible that serous tumors are the only subtype related to
a BRCA1 or BRCA2 mutation. Furthermore, fallopian tube carcinoma occurred
more often in BRCA mutation carriers than in the reference population.
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Chapter 4
Dysplastic changes in prophylactically removed Fallopian
tubes of women predisposed to developing ovarian cancer
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Peter Kenemans (1) and René H. M. Verheijen (1)
(1) Department of Obstetrics and Gynaecology, (2) Department of Pathology
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Abstract
The aim of this study was to investigate the occurrence of (pre)neoplastic
lesions in overtly normal Fallopian tubes from women predisposed to developing
ovarian carcinoma.
The presence of (pre)neoplastic lesions was scored in histological specimens from
12 women with a genetically determined predisposition for ovarian cancer, of whom
seven tested positive for a germline BRCA1 mutation. A control group included
13 women. Immunohistochemistry was used to determine the expression of p21,
p27, p53, cyclin A, cyclin D1, bcl-2, Ki67, HER-2/neu, and the oestrogen and
progesterone receptors. Loss of heterozygosity (LOH) analysis on the BRCA1
locus was also assessed on dysplastic tissue by PCR studies.
Of the 12 women with a predisposition for ovarian cancer, six showed dysplasia,
including one case of severe dysplasia. Five harboured hyperplastic lesions and
in one woman no histological aberrations were found in the Fallopian tube.
No hyperplastic, dysplastic or neoplastic lesions were detected in the Fallopian
tubes of control subjects. In the cases studied, morphologically normal tubal
epithelium contained a higher proportion of Ki67-expressing cells ( p=0.005)
and lower fractions of cells expressing p21 (p<0.0001) and p27 (p=0.006) than
in the control group. Even higher fractions of proliferating cells were found in
dysplastic areas (p=0.07) and accumulation of p53 was observed in the severely
dysplastic lesion. Expression patterns of other proteins studied, including the
hormone receptors, were similar in cases and controls. One subject, a germline
BRCA1 mutation carrier, showed loss of the wild-type BRCA1 allele in the severely
dysplastic lesion. 
In conclusion, the Fallopian tubes of women predisposed to developing ovarian
cancer frequently harbour dysplastic changes, accompanied by changes in
cell-cycle and apoptosis-related proteins, indicating an increased risk of developing
tubal cancer.
Introduction
It is estimated that 90% of hereditary ovarian cancer cases are caused by a mutation
in the BRCA1 gene (1).
In the remaining group of hereditary cancer cases, other genes, such as BRCA2,
are involved (2). In view of the supposed sequence of simple hyperplasia into
atypical hyperplasia, to dysplasia, and finally into invasive carcinoma, hyperplastic
and dysplastic changes are expected to be present in a relatively high proportion
of prophylactically removed ovaries. Indeed, larger nuclei and denser chromatin
have been reported in prophylactically removed ovaries from women predisposed
to developing ovarian carcinoma when compared with non-predisposed controls
(3,4). More recent data confirm that ovarian dysplasia can be related to loss of
BRCA1 function (5).
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Some reports noted the occurrence of tubal cancer in families in which BRCA1 or
BRCA2 mutations segregate (6–9). Recently, we presented molecular evidence that
Fallopian tube adenocarcinoma is part of the cancer spectrum in BRCA1 mutation
carriers (10). Although the pathogenesis of Fallopian tube cancer is poorly
understood, it has been suggested that the commonly assumed epithelial cancer
progression model also applies to Fallopian tube carcinoma (11). This model
presumes the presence of hyperplastic and dysplastic changes in the Fallopian tubes
of women predisposed to developing ovarian cancer, but such data have not yet
been published. We therefore screened sections of Fallopian tubes, prophylactically
removed from women with a high, genetically determined risk of developing
ovarian cancer, for the presence of hyperplastic and dysplastic lesions. In addition,
we assessed the expression of cell-cycle and apoptosis-related proteins and the
expression of the oestrogen and progesterone receptors known to be involved in
epithelial carcinogenesis (12–14). Finally, we investigated the potential contribution
of BRCA1 inactivation to the pathogenesis of these lesions.
Materials and methods
Patients
We studied 20 buffered formaldehyde-fixed, paraffinembedded Fallopian tube
samples derived from the fimbrial and/or middle or isthmic parts, from 12 women
with a genetically determined predisposition to develop ovarian cancer, defined
as the occurrence of breast and/or ovarian carcinoma in at least three firstdegree
family members and at least two in consecutive generations; and one patient with
a diagnosis of breast or ovarian carcinoma before the age of 50. These women
underwent prophylactic adnexectomy between 1997 and 1999 (Table 1). Of these
women, seven harboured a BRCA1 mutation. All women were considered healthy
at the time of surgery. No abnormalities were found at ultrasonography of the small
pelvis performed preceding the procedure. CA-125 levels were within the
physiological range (<35 kU/l). The median age of these women was 49.4 years
(range 44–59 years). Bilateral adnexectomy was performed laparoscopically under
general anaesthesia. A control group consisted of 18 Fallopian tube samples derived
from 13 women without a genetically determined risk of developing cancer,
undergoing adnexectomy for benign gynaecological disease (n=6) or sterilization
procedures (n=7) during Caesarean section. The median age of these women
was 46.1 years (range 31–72 years). No signs of salpingitis were detected in
these women.
Histology and immunohistochemistry 
Morphological assessment was performed routinely on 4 mm thick haematoxylin
and eosin (H&E)-stained sections. Sections, mounted on poly-l-lysine-coated
slides, were used for immunohistochemistry. For classification of dysplastic and
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hyperplastic changes, the criteria of Fox and Wells (11) were used.
Immunohistochemistry was performed according to the manufacturer’s
recommendations with mouse monoclonal antibodies to the following cell-cycle-
related proteins and receptors: Ki67 (MIB1, Immunotech, Marseille, France),
p53 (BP53-12, Bioprobe, Amstelveen, The Netherlands), bcl-2 (m887, Dako,
Copenhagen, Denmark), cyclin D1 (M5210p, Neomarkers, Fremond, USA) cyclin
A (Ncl-cyclA, Novocastra, Newcastle upon Tyne, UK), p27 (k25020, Transduction
Laboratories, Lexington, USA), p21 (WAF1, Oncogene, San Diego, USA ), oestrogen
receptor-alpha (ER, M7047, Dako, Copenhagen, Denmark), progesterone receptor
(PR, Ncl-pgr, Novocastra, Newcastle upon Tyne, UK), and HER-2/neu (3B5,
courtesy of Dr M. J. van de Vijver, Netherlands Cancer Institute, Amsterdam, The
Netherlands). Slides were washed with phosphatebuffered saline (PBS) between
steps. First, slides were dewaxed. Endogenous peroxidase activity was blocked with
0.03% hydrogen peroxide in methanol for 10 min. Next, antigen retrieval was
performed in 10 mM citrate buffer at pH 6.0 at 100°C in a microwave oven. After
cooling down, the samples were preincubated with a solution of 10% normal rabbit
serum diluted in PBS with 0.05% saponin for 100 min. Slides were then exposed to
primary antibodies overnight at 5°C. The following day, slides were exposed in
sequence to biotinylated rabbit anti-mouse antibodies (1 : 500) diluted in PBS and
1% bovine serum albumin for 60 min. The slides were developed using 0.05% 3,3’-
diaminobenzidine tetrahydrochloride dihydrate containing 0.02% hydrogen
peroxide. Slides were counterstained with haematoxylin and mounted in DePeX
mounting medium (BDH Laboratory Supplies, Poole, UK) after dehydration.
In negative controls, the primary antibody was omitted and PBS was used.
Positive controls (p21 and p27: provided by the manufacturer; p53 and HER-2/neu:
breast carcinoma; ER and PR: ovary, cyclin A, Ki67; and bcl-2: tonsil) were used
throughout. For p21, p27, p53, cyclin D1, ER, and PR, the percentages of positive
nuclei, and for bcl-2 staining the percentage of cells with cytoplasmic positivity,
were visually estimated by consensus of two observers (PJvD and JMJP). For HER-
2/neu, only membrane staining was considered positive. Percentages of Ki67-
and cyclin A-positive cells were counted by semi-automated stereology-driven
immunoquantitation using the QPRODIT system (Leica, Cambridge, UK) in at
least 500 nuclei (or the total number of nuclei) sampled systematically at random
(15). Histologically defined dysplastic and non-dysplastic areas were assessed
separately. Statistical analysis was performed by use of the Mann–Whitney and
Wilcoxon rank sum tests.
DNA analysis
BRCA1 and BRCA2 mutation screening had been  performed in 11 of 12 cases with
a predisposition for ovarian cancer by the protein truncation test (Table 1), followed
by direct sequencing as described in detail before (16). To study whether loss of the
wild-type BRCA1 allele had occurred in dysplastic lesions, areas of dysplasia as well
as areas of histologically normal tubal tissue were laser microdissected (17) from
10 mm thick paraffin sections, guided by control H&E-stained sections on which
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areas of dysplasia had been marked by a pathologist (PJvD). DNA was extracted in
a 15 µl lysis solution [100 mM Tris–HCl, pH 8.8; 2 mM EDTA; and 400 µg/ml
proteinase K (Boehringer Mannheim, Basel, Switzerland)] and incubated overnight
at 56°C. The samples were boiled for 8 min to inactivate proteinase K. For LOH
analysis, three BRCA1 primers (D17S855, D17S1322, D17S1323) were used.
One microlitre of DNA template was amplified in a 15 µl polymerase chain reaction
(PCR) containing 10 mM Tris–HCl buffer (pH 8.3), 50 mM KCl, 1.5 mM MgCl2,
0.001% (w/v) gelatin, 200 µM of each dNTP, 0.2 µM of each primer, 200 µM of
Cy5-dCTP, and 1 Unit of AmpliTaq-gold (Perkin-Elmer, Norwalk, CT, USA). PCR
was carried out on a thermal cycler (PTC-100, MJ Research Inc., Watertown, USA)
under the following conditions: initial denaturation at 94°C for 12 min, followed
by 38 cycles of 94°C for 1 min, 55°C for 1 min, and 72°C for 1 min. Terminal
extension was achieved at 72°C for 5 min. One microlitre of PCR product, 2 µl
of loading dye, 0.0375 ml of 100 bp standard, and 0.0375 ml of 150 bp standard
(Visible Genetics, Toronto, Canada) were used on a long-read tower (Visible
Genetics, Toronto, Canada) for LOH analysis.
In one case, LOH was detected and to assess which BRCA1 allele was lost,
light-cycler PCR melting curve analysis (Roche Diagnostics, Indianapolis, USA)
was performed as described by Pals et al. (18). In short, PCR products were designed
around the BRCA1 mutation by use of primers surrounding the mutation using
OLIGO5 software (National Biosciences Inc., Plymouth, USA). Hybridization probe
sets were designed for the PCR product, using OLIGO5, each probe overlapping
the mutation. The end of the sense probe was labelled with fluorescein
isothiocyanate and the end of the antisense probe with LightCycler Red 640
(Roche Diagnostics, Indianapolis, USA). Hybridization probe reactions were
performed according to the LightCycler kit instructions (DNA master hybridization
probes), using master mixes and 0.5 µM of each primer. The annealing temperature
used was 56°C and 55 cycles were performed. At the end of the PCR cycles,
conventional melting curve analysis (LightCycler kit instructions) was performed by
heating to 95°C for 5 min, followed by cooling to 45°C and gradual heating to 72°C.
Results
BRCA1 status and histology
Table 1 shows the age at prophylactic adnexectomy, BRCA mutation status
(7/12 cases with BRCA1 germline mutation, no BRCA2 mutations), and the presence
of tubal epithelial abnormalities in the 12 cases. Figure 1 shows a representative
example of a dysplastic area as observed in epithelium of Fallopian tubes of
the cases. All of the BRCA1 mutation carriers showed either hyperplastic (n=5)
or dysplastic (n=6) foci. We did not detect morphological aberrations in tubal
epithelium in only one of the predisposed women without a confirmed BRCA1
mutation. Interestingly, the dysplastic areas showed no ciliated cell types. In six
out of 12 cases, we were able to retrieve more than one paraffin-embedded Fallopian
tube section. In four of these samples, we found histological aberrations in all
sections studied. In three out of 13 controls, we were able to retrieve more than
one sample. None of these showed evidence of disease.
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Cell-cycle proteins and steroid receptors
In accordance with our previous observations (9), ER-alpha was observed in
both secretory and ciliated cells with, in most samples, a preference for peripherally
located cells. The expression of p21 was only observed in ciliated cells, and bcl-2
only in secretory cells. PR was abundantly expressed in both cell types. Cyclin D1
staining was observed in nuclei of the severely dysplastic lesion, whereas in other
samples, only focal cytoplasmic staining was observed. HER-2/neu membrane
staining was not seen at all. Staining for p53 was weak and infrequent in
non-dysplastic areas of both cases and controls, pointing to expression of wild-type
protein. In the morphologically normal Fallopian tube epithelium, ovarian
cancer-predisposed cases showed significantly higher percentages of Ki67 positivity
(p=0.005). Furthermore, significantly lower percentages of p21- ( p<0.001) and
p27- ( p=0.006) positive cells were detected in normal epithelium from predisposed
women than from control subjects. There were no significant differences for ER,
PR, cyclin A, p53, bcl-2, and HER-2/neu. The dysplastic areas showed even higher
proportions of Ki67-positive cells than the non-dysplastic areas of predisposed
women ( p=0.07) and were exclusively bcl-2-positive, due to lack of ciliated cells.
A positive trend was detected in the expression of p27, in which p27 was expressed
in a higher proportion of cells in dysplastic areas than in the morphologically
normal epithelium of cases ( p=0.089). The fraction of cells expressing p53 was
Table 1.  Age at adnexectomy, BRCA1 mutation status, and histological data of Fallopian tube
epithelium from 12 women with a hereditary risk of ovarian cancer
Cases Age BRCA1 mutation Morphology
1 45 Ivs 21-37 del 1510bp Dysplastic
2 45 1410 ins T Hyperplastic
3 47 5396 + 1 G -> A Hyperplastic
4 48 2805 del AA Dysplastic
5 49 2804 del AA Hyperplastic
6 53 185 del AG Dysplastic
7 59 3109 ins AA Dysplastic
8 44 No mt. found in family Hyperplastic
9 46 No mt. screening done Hyperplastic
10 50 No mt. found in family Dysplastic
11 50 No mt. found in family No abnormalities
12 57 No mt. found in family Dysplastic
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increased within the one severely dysplastic lesion, compared with the
morphologically normal epithelium of cases. This concurred with cyclin D1
expression in some cells. For the remaining proteins, no differences were observed
between morphologically normal and dysplastic areas of cases.
BRCA1 analysis
In one case, case 7, LOH of BRCA1 was detected in the dysplastic cells using the
D17S1322 primer set. In all other germline BRCA1 mutation carrier cases, the
dysplastic cells retained the studied loci (D17S855, D17S1322, and D17S1323).
Light-cycler PCR and melting curve analysis were performed to verify the LOH
result and to assess which BRCA1 allele was lost. The observed LOH of case 7 was
confirmed. In the melting curve of amplified DNA from dysplastic tissue, only the
left peak is present, indicating that the wild-type allele of BRCA1 is lost in the
dysplastic epithelium of the Fallopian tube of this case (Figure 2).
Discussion
The presence of dysplasia in six out of 12 cases (including one case of severe
dysplasia) suggests that preneoplastic changes are a common phenomenon in
Figure 1.  Dysplastic area: A) H&E staining; B) Ki67 expression; C) cyclin D1 expression;
D) ˜p53 expression. (x 63  obj.)
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the macroscopically normal Fallopian tubes of women predisposed to developing 
ovarian carcinoma. Five cases showed hyperplastic changes, which may not be
preneoplastic, as they are also found in cases of salpingitis (20,21). Since in most
cases these aberrations were observed in various sections of different parts of the
tube, such lesions may be multifocal. As we completely embedded the samples from
the cases and not always from the controls, one could argue that the more intensive
sampling strategy in the cases resulted in the increased frequency of hyperplasia
and dysplasia. However, as described in the Materials and methods section,
sampling was not much different between cases and controls, as in 6/12 cases
and 3/13 controls we were able to retrieve more than one block. In four of the
samples derived from cases, we found histological aberrations in all sections studied
and no evidence of disease in the controls, even those with more than one block.
We think, therefore, that the selective finding of dysplasia in the cases studied has
not been influenced by the sampling procedure and can be regarded as a true
finding. The increased proliferation fraction in Fallopian tube epithelia from women
with predisposition to ovarian cancer is compatible with a higher tendency to
develop into malignancy. Our immunohistochemical studies show that the fraction
of p21-expressing cells is decreased in normal-appearing tubal epithelium of women
with a predisposition as compared with controls. This may be caused by a failure of
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Figure 2. Melting curves of the light-cycler PCR products of DNA dissected from a severe dys-
plastic area of case 7. In the dysplastic epithelium, the wild-type product is lost (see
text). Melting temperature for probes in the case of the 3109 ins AA mutation: 52.4°C.
In the case of the wild-type allele: 57.8°C.
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the mutated BRCA1 gene product to activate the p21 promoter (22). Also, p27
expression was suppressed in normal-appearing epithelium of the tubes from
predisposed women. The exact molecular effect of the presence of a mutated BRCA1
gene product in cells on p27 expression remains to be elucidated. Expression of p53
was slightly increased in normal epithelium of cases compared with controls but this
expression was still considered to be of the wild-type form. Mean p53 expression
showed an increase in dysplastic areas. Dysplastic areas consisted of cells with a
secretory phenotype. These lesions were also completely positive for bcl-2, which is
in concordance with our previous publication (19). These observations indicate a
shift towards the secretory phenotype in dysplastic progression, with complete loss
of ciliated cells. bcl-2 is known as an anti-apoptotic protein in haematological cells,
but in epithelial cells its function is perceived differently. Normal cells and well-
differentiated epithelial cancers, in the breast and ovary for example, are bcl-2-
positive, and poorly differentiated lesions show loss of bcl-2 expression, without
correlation with apoptosis. In epithelial lesions, bcl-2 seems therefore to play a role
in differentiation rather than apoptosis (23,24).
The other cell-cycle-related proteins studied did not show a significant
difference between cases and controls, but percentages of positive cells fluctuated
between samples. This fluctuation might be influenced by differences in the
hormonal status of the women studied.
In one of seven cases with a BRCA1 germline mutation, loss of the wild-type BRCA1
allele and accumulation of p53 were detected. Generally, loss of the wild-type allele in
BRCA1 carriers is considered to be the first hit in tumourigenesis (25). This particular
sample also showed accumulation of p53. Overexpression of p53 can occur in cancers
in which no TP53 gene mutation is detected, but some studies do show a correlation
between p53 overexpression and a mutated TP53 gene (26,27). Our material was not
sufficient to perform p53 mutation analysis. It is tempting to speculate that in this case
we observed mutated p53 expression, but we have no firm proof of this. Since after the
elimination of the wild-type BRCA1 allele at least one checkpoint tumour suppressor
gene, such as p53, should be affected to facilitate development into malignancy, the
dysplastic process in this sample may have reached a final preneoplastic stage, prior to
developing into invasive carcinoma. However, preneoplastic changes and changes in
the expression of cellcycle-related proteins p21 and p27 were also detected in the other
six BRCA1 mutated cases in which no LOH of BRCA1 was detectable. This suggests
that the presence of only one defective BRCA1 allele is already able to deregulate
proliferation in Fallopian tube epithelium. In cases without a detected BRCA1
mutation, similar aberrations were found. This implies either that these women with
an increased risk of ovarian carcinoma carry an undetected BRCA1 mutation (16), or
that other unknown mechanisms play a role in tubal epithelial derailment.
Dysplastic changes and changes in the expression of proteins involved in cell-cycle
regulation are likely to indicate an increased risk of the development of Fallopian
tube adenocarcinoma, which may in fact be more common than is often assumed in
women predisposed to developing ovarian carcinoma. It has been reported that
tubal cancer is an under-recognized form of gynaecological cancer (28). Since tubal
cancer usually presents at an advanced stage, with the adjacent ovary often
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completely involved in the tumour process, it may be mistaken for primary ovarian
cancer. Fallopian tube carcinoma is only diagnosed if (1) the tumour bulk is
present in the Fallopian tube, (2) the tumour arises from the endosalpinx, (3) the
histological pattern of the tumour reproduces the epithelium of the tubal mucosa,
and (4) a transition from benign to malignant epithelium of the tubal wall is
demonstrated (29). As the Fallopian tube epithelium shares many properties with
the ovarian surface epithelium, the tumours derived from these tissues can be
morphologically and immunohistochemically indistinguishable. A diagnosis of
primary Fallopian cancer can be made only when the ovaries are either normal,
or contain obviously less tumour tissue than the tube.
In conclusion, we have provided evidence that hyperplastic and/or dysplastic
changes in epithelium of Fallopian tubes are common in women predisposed to
developing ovarian carcinoma. These changes seem to concur with deregulation of
cell-cycle-related proteins, followed by the loss of BRCA1. The observed epithelial
aberrations seem to be present in most women with a hereditary predisposition for
ovarian cancer. This indicates that prophylactic surgery in women with a family
history of breast/ovarian cancer should include both the ovaries and the Fallopian
tubes. Moreover, to attain more insight into BRCA1-related oncogenesis, the
ovaries and Fallopian tubes should both be examined in all such cases.
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Chapter 5
Expression of differentiation and proliferation related
proteins in epithelium of prophylactically removed ovaries
from women with a hereditary female adnexal cancer
predisposition
Jurgen M.J. Piek (1), René H.M. Verheijen (1), Fred H. Menko (2),
Ans P.M. Jongsma (1), Jitske Weegenaar (1), Johan J.P. Gille (2),
Gerard Pals (2), Peter Kenemans (1), Paul J. van Diest (3)
Departments of Obstetrics and Gynaecology (1), Clinical Genetics and Human
Genetics (2) and Pathology (3), VU University Medical Centre, Amsterdam,
The Netherlands
Histopathology; 43: 26–32
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Abstract
Aims: To investigate the occurrence of preinvasive neoplastic lesions in ovarian
surface epithelium and ovarian inclusion cyst epithelium of women with a
hereditary predisposition to the development of female adnexal (ovarian and
fallopian tube) carcinoma and to assess the expression of differentiation and
proliferation related proteins within putative sites of origin of serous ovarian
carcinoma, the ovarian surface epithelium and ovarian inclusion cyst epithelium.
Methods: Twenty-one ovaries, prophylactically removed from 11 women
predisposed to the development of female adnexal cancer (cases) were compared
with 22 ovaries from 11 women without such predisposition (controls).
Archival histological specimens were screened for hyperplastic and dysplastic
epithelial lesions. In both the ovarian surface and inclusion cyst epithelia, the
percentage of cells was determined that stained positively for Ki67, p21, p27, p53,
cyclin A, cyclin D1, bcl-2 and the presence of HER-2 /neu, oestrogen (ER-alpha)
and progesterone receptors (PR).
Results: No preinvasive neoplastic lesions were detected. However, hyperplastic
areas were found in three cases and in four controls (NS). ER-alpha (P = 0.013),
PR (P < 0.001), bcl-2 (P = 0.008), p21 (P = 0.046) and p27 (P = 0.008) were
expressed in a significantly higher percentage of cells in inclusion cyst epithelium
than in ovarian surface epithelium (both groups). The latter showed higher bcl-2
expression in cases (P = 0.05) compared with controls. The inclusion cyst
epithelium of cases showed higher expression of bcl-2 (P = 0.006) and PR (P =
0.039) compared with controls. Proliferation was low in both cases and controls
as reflected by low Ki67 expression. Overexpression of p53, cyclin D1 and
HER-2 /neu was not detected.
Conclusions: Premalignant changes are not a common feature of ovaries removed
prophylactically from women predisposed to the development of female adnexal
carcinoma. Increased expression of p21, p27, and ER-alpha is seen in inclusion cyst
compared with ovarian surface epithelium of women with and without an inherited
risk of adnexal carcinoma. This is most probably caused by the different
intraovarian hormonal milieu of inclusion cyst epithelium. However, the increased
expression of bcl-2 and PR in the inclusion cyst epithelium of patients with a
hereditary predisposition may reflect early disruption of hormonal balance and
growth control.
Introduction
Cancer of the ovary is among the most common female genital tract cancers and
has the worst prognosis. However, little is known about the carcinogenic pathways,
even in BRCA1 /2 mutated patients that are at high risk of developing ovarian
and fallopian tube cancer (from now on referred to as female adnexal carcinoma). 
For serous cancers, the most common histological type in both sporadic and
104
E
xp
re
ss
io
n 
of
 d
iff
er
en
tia
tio
n 
an
d 
pr
ol
ife
ra
tio
n 
re
la
te
d 
pr
ot
ei
ns
 in
 e
pi
th
el
iu
m
 o
f 
pr
op
hy
la
ct
ic
al
ly
 r
em
ov
ed
 o
va
rie
s 
fr
om
 w
om
en
 w
ih
t 
a 
he
re
di
ta
ry
 f
em
al
e 
ad
ne
xa
l c
an
ce
r 
pr
ed
is
po
si
tio
n
hereditary cases, the ovarian surface epithelium and inclusion cyst epithelium
have been proposed as sites of origin of epithelial ovarian cancer. Dysplastic ovarian
surface epithelium, also referred to as ovarian intraepithelial neoplasia (1-3), and
an increased frequency of epithelial inclusion cysts have been observed in ovaries
removed prophylactically from women at high risk of developing female
adnexal cancer (4-7).
Recently, we showed that dysplastic lesions, strongly expressing bcl-2, are
quite common in fallopian tubes of genetically predisposed patients undergoing
prophylactic adnexectomy (8) underlining the increased risk for serous fallopian
tube cancer in these patients (9). Furthermore, we detected changes in the cell
cycle-related proteins Ki67, p21 and p27 in normal fallopian tube epithelium
from genetically predisposed women, perhaps reflecting early genetic changes
contributing to the predisposition of developing serous tubal cancer. In view of
the similarities between serous fallopian tube and ovarian cancers, similar
carcinogenic pathways could underlie both types of neoplasms (10). Until now,
neither normal ovarian surface or inclusion cyst epithelium have been studied
with respect to the expression of the above mentioned proteins.
The aims of this study were therefore to evaluate the occurrence of preinvasive
neoplastic changes in prophylactically removed ovaries of women with a genetic
predisposition to female adnexal cancer and to assess the expression of proliferation
and differentiation related proteins [Ki67, p21, p27, p53, cyclin A, cyclin D1, bcl-2,
HER-2/neu, oestrogen (ER-alpha) and progesterone receptors (PR)] in these ovaries
in comparison with control ovaries removed for reasons other than ovarian or
tubal pathology.
Methods
patients
Twenty-one buffered formaldehyde-fixed paraffinembedded ovaries (completely
embedded apart from a  small piece which was frozen in liquid nitrogen) were
studied from 11 women with a genetically determined predisposition to the
development of female adnexal carcinoma, defined as: breast and / or ovarian /
fallopian tube carcinoma in at least three first-degree family members including
the index patient, at least two carcinomas in consecutive generations, or one patient
with a diagnosis of breast carcinoma before the age of 50. Seven of these patients
harboured a BRCA1 mutation, and the other four fulfilled the abovementioned
criteria. These women underwent bilateral laparoscopic prophylactic adnexectomy
under general anaesthesia between 1997 and 1999. No abnormalities were found at
ultrasonography of the pelvis performed prior to the procedure. CA 125 levels were
within normal limits. The median age of these women was 48.7 years (range 44–59
years). Twenty-two ovaries derived from 11 women without a family history of
female adnexal or breast cancer served as controls. These ovaries were also halved
and totally embedded into two blocks. These women underwent oophorectomy
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during surgery unrelated to ovarian or tubal pathology. The median age of this
control group was 55.2 years (range 30–72 years), not significantly different from
the cases (P = 0.09). At the time of oophorectomy, five cases were premenopausal
versus two controls. Of these, three patients used oral contraceptives as well as both
control patients. Five cases and one control were peri-menopausal. One case and
eight controls were post-menopausal. 
Histology and Immunohistochemistry
Morphological assessment was carried out routinely on 4 uM thick haematoxylin
and eosin-stained sections. For classification of hyperplastic and dysplastic
changes the criteria of Resta et al.(11,12) and Deligdisch et al (13) were applied.
Briefly, hyperplasia was defined as a multilayer of cells with round to oval nuclei,
whilst dysplasia showed superimposed hyperchromasia and / or atypia of nuclei.
Paraffin sections (4 uM thick), mounted on polyl-lysine coated slides, were used
for immunohistochemistry. Mouse monoclonal antibodies to the following cell
cycle-related proteins and receptors were applied: Ki67 (MIB1; Immunotech,
Marseille, France), p21 (WAF1; Oncogene, San Diego, CA, USA), p27 (k25020;
Transduction Laboratories, Lexington, KY, USA), p53 (BP53-12; Bioprobe,
Amstelveen, the Netherlands), cyclin A (Ncl-cyclA; Novocastra, Newcastle
upon Tyne, UK), cyclin D1 (M5210p; Neomarkers, Fremont, CA, USA), bcl-2
(m887; Dako, Copenhagen, Denmark), HER-2 / neu receptor (3B5; courtesy of
Dr M. van de Vijver, Netherlands Cancer Institute, Amsterdam, the Netherlands),
oestrogen receptor-alpha (ER, M7047; Dako) and both progesterone receptor
isotypes (PR, Ncl-pgr; Novocastra). Immunohistochemistry was performed as
previously described (8). Briefly, slides were dewaxed, using xylene. Then
endogenous peroxidase activity was blocked with 0.03% hydrogen peroxide. Antigen
retrieval was performed by repeated microwave heating in citrate buffer.
Preincubation was carried out with 10% normal rabbit serum. Overnight exposure
to primary antibodies was performed at 4 degrees Celsius. For negative controls
the primary antibody was omitted and PBS was used. Visualization was performed
with 3,3’-diaminobenzidine tetrahydrochloride dihydrate. Positive controls (for p21
and p27 provided by the manufacturer, for p53 and HER-2 / neu a known positive
breast carcinoma, for oestrogen and progesterone receptors a normal fallopian
tube and a tonsil for cyclin A, cyclin D1, Ki67 and bcl-2) were used throughout.
The percentage of cells with positive nuclei and for bcl-2 the fraction of cells with
cytoplasmic positivity were counted by two observers (P.J.v.D., J.M.J.P.) on a
double-headed microscope, using the consensus score. All epithelial cells on the
ovarian surface and lining inclusion cysts were examined. For HER-2 / neu only
membrane staining was considered positive. Statistical analysis was performed
using the Mann–Whitney, chi-square and Wilcoxon rank sum tests.
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Results
morphological changes 
Table 1 shows the age at prophylactic adnexectomy, mutation status of the seven
mutation carriers and the presence of epithelial abnormalities in the 11 cases
studied. Table 2 shows similar data on the controls. Hyperplasia was found in
the ovarian surface epithelium of three cases and four controls (Figure 1A).
Moreover, it was detected in the inclusion cyst epithelium in two cases. In one case
a mucinous cystadenoma was detected. Surface papillomatosis was observed in
one case, and in three controls (Figure 1B). Cells with a distinct tubal phenotype
(alternating serous and ciliated cells) were observed in inclusion cyst epithelium
in three cases and three controls (Figure 1C). No cells with a tubal phenotype were
seen in ovarian surface epithelium. 
Cell Cycle-related Proteins and Steroid Receptors
Table 3 and Figure 2 summarize the results of the immunohistochemical analysis.
The ovarian surface epithelium of cases showed greater expression of bcl-2
(P = 0.05) compared with controls. Ki67 expression was low (<1%) in both cases
and controls (P = 0.635) and expression of p21 was only found in a few cells of five
cases and four controls (P = 0.683). No significant differences were detected in
the expression of oestrogen receptor (P = 0.331), p27 (P = 0.196) or progesterone
receptor (P = 0.95). No expression of cyclin D1, and no over-expression of p53
or HER-2 / neu were detected.
In inclusion cyst epithelium, progesterone receptor (P = 0.039) and bcl-2
(P = 0.006) were expressed significantly greater in cases compared with controls.
Expression of cyclins A and D1 and over-expression of p53 and HER-2 / neu
were not detected at all.
In hyperplastic areas, no significant differences were found in the expression
of oestrogen or progesterone receptors, bcl-2 or p27 compared with normal
epithelium. No expression of cyclin D1 or p21 and no overexpression of HER-2 / neu
was detected in these areas.
Discussion
In this study preinvasive neoplastic lesions were undetected in prophylactically
removed ovaries from women predisposed to develop female adnexal carcinoma.
Hyperplasia, which is by no means necessarily premalignant, was detected in three
cases but also in four controls. This is in contrast to our previous observation in
fallopian tubes of the same subset of cases, in which a high incidence (42%) of
dysplastic changes was observed (8). Our observation in these ovaries is in line with
recent reports (14,15). However, earlier studies reported premalignant changes to
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Table 1. Age at oophorectomy, morphology of ovarian surface epithelium (OSE)
and inclusion cyst epithelium (ICE): ovarian (OSE-like = flat to cuboidal cells)
or tubal (alternating serous and ciliated cells) type, of 11 women with (cases)
a hereditary predisposition to the development of female adnexal cancer undergoing
prophylactic surgery
Cases Age BRCA1 mutation Morphology OSE Morphology ICE ICE ICE
(ovarian type) (tubal type)
1 45 IVS 21-37 del 1510bp no abnormalities hyperplasia X X
2 45 1410 ins T surface no abnormalities X X
papillomatosis
3 47 IVS20 + 1G>A no abnormalities no abnormalities X -
4 48 2805 del AA no abnormalities hyperplasia X -
5 49 2804 del AA no abnormalities no abnormalities - -
6 53 185 del AG hyperplasia no abnormalities X -
7 59 3109 ins AA hyperplasia no abnormalities X -
8 44 no mt. found in family no abnormalities mucinous - -
cystadenoma
9 46 no mt. screening hyperplasia no abnormalities - X
10 50 no mt. found in family no abnormalities no abnormalities - -
11 50 no mt. found in family no abnormalities no abnormalities X -
Table 2. Age at and indication for oophorectomy, morphology of ovarian surface epithelium
(OSE) and inclusion cyst epithelium (ICE): ovarian (OSE-like = flat to cuboidal cells)
or tubal (alternating serous and ciliated cells) type, of 11 women without (controls)
a hereditary predisposition to the development of female adnexal cancer
Controls Age Indication Morphology OSE Morphology ICE ICE ICE
(ovarian type) (tubal type)
1 51 ovarian cyst surface no abnormalities X X
papillomatosis
2 53 ovarian cyst hyperplasia no abnormalities X -
3 69 endometrial no abnormalities no abnormalities - X
carcinoma
4 51 ovarian cyst hyperplasia no abnormalities - -
5 55 ischaemic enteritis no abnormalities no abnormalities X -
6 61 endometrial atypia no abnormalities no abnormalities X -
7 54 endometrial surface no abnormalities X -
carcinoma papillomatosis
8 72 endometrial atrophy surface no abnormalities X -
papillomatosis
9 40 ovarian cyst hyperplasia no ICE found - -
10 72 endometrial carcinoma no abnormalities no abnormalities X X
11 30 transgender hyperplasia no ICE found - -
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be more common in prophylactically removed ovaries (4-6). One explanation for
this discrepancy might be the use of different and, as yet, not well defined criteria
for the diagnosis of premalignant changes in the different studies.
One common theory holds that ovarian epithelial cancer arises from the ovarian
surface epithelium itself or from the epithelial-lined inclusion cysts, either de novo
(16) or through tubal metaplasia (17). In contrast to ovarian surface epithelium,
inclusion cyst epithelium is not separated from the hormone-producing ovarian
stroma by the tunica albuginea, which forms a tight barrier between ovarian surface
epithelium and stroma (3). Thus, altered expression of cell cycle-related proteins
and receptors in inclusion cyst compared with ovarian surface epithelium may, in
part, be explained by the different hormonal milieu brought about by hormones
produced by the ovarian stroma. This applies especially to p21, p27, and oestrogen
receptor which showed greater expression in the inclusion cyst compared with
ovarian surface epithelium of both cases and controls. However, there was a
significant increase in expression of bcl-2 in surface epithelium and of bcl-2 and
progesterone receptor in inclusion cyst epithelium of patients with a hereditary
predisposition. The latter suggests that there may be a different stromal hormonal
environment in hereditary patients. Oestrogen produced by the ovarian stroma may
also be responsible for up-regulation of progesterone receptor expression (18). We
believe the increased bcl-2 expression of both ovarian surface and inclusion cyst
epithelium to be a harbinger of premalignant neoplastic change, as we have
observed similar changes in the tubal epithelium of patients with a hereditary
predisposition (8). In view of its anti-apoptotic function, increased bcl-2 expression
could lead to a growth advantage, but proliferation (as reflected by Ki67 staining)
was comparatively low (<1%) in both the ovarian surface and inclusion cyst
epithelium of cases and controls, as also reported by others (19). This indicates that
increased proliferation of ovarian epithelial cells is not a common feature in ovaries
of patients with a hereditary predisposition to female adnexal cancer, in contrast to
our previous findings in the fallopian tubes of these women (8).
Table 3. Median percentage of cells positively stained for the listed proliferation and
differentiation markers in ovarian surface epithelium and inclusion cyst epithelium
of patients with a hereditary predisposition to female adnexal cancer and controls,
(NS = not significant)
Marker Normal Ovarian Surface Epithelium Normal Inclusion cyst Epithelium
Controls Cases p Controls Cases p
(range) (range) (range) (range)
Ki67 0 (0-1) 0 (0-1) ns 0 (0-2) 0 (0-1) ns
p27 35 (0-100) 46 (0-100) ns 56 (3-100) 67 (0-100) ns
bcl-2 18 (0-50) 47 (2-100) 0.05 29 (0-100) 77 (0-100) 0.006
ER-alpha 35 (0-90) 23 (0-80) ns 57 (5-90) 43 (0-100) ns
PR 19 (0-75) 40 (0-100) ns 60 (10-90) 82 (10-100) 0.039
p53 0 0 ns 0 0 ns
Cyclin D1 0 0 ns 0 0 ns
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In hyperplastic surface epithelial lesions, no differences in expression of the proteins
studied were found compared with the morphologically normal surface epithelium,
underlining the fact that these lesions may not necessarily be premalignant at all.
p53 expression was low in both the studied groups, with only occasional weak
nuclear staining suggesting the presence of wild-type protein. This is in agreement
with a recent report (19) in which p53 was rarely expressed in the nuclei of inclusion
cyst epithelium and was undetected in surface epithelium. 
Previously, we described high accumulation of p53 in hereditary ovarian cancer
(20) so p53 mutation is apparently not the earliest event in (hereditary) ovarian
Figure 2: Expression of variously indicated proliferation and differentiation markers in
ovarian inclusion cyst epithelium.
Figure 1: A, Haematoxylin–eosin staining of a hyperplastic lesion of the ovarian surface
epithelium. B, Haematoxylin–eosin staining of surface papillomatosis of the ovarian
surface epithelium. C, bcl-2 staining of an inclusion cyst lined by cells of tubal
phenotype. †Serous cell; ‡ciliated cell.
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carcinogenesis, but is still likely to be important in ovarian carcinogenesis itself.
In one study p53 immunoreactivity was detected in 63% of foci of putative
preinvasive neoplasia related to serous ovarian carcinomas (21). 
HER-2 / neu (22) and cyclin D1 (23–25) have been implicated in ovarian
carcinogenesis. No expression was detected in this study, indicating that the
expression of the HER-2 / neu membrane receptor and cyclin D1 are probably late
events in ovarian carcinogenesis. 
In conclusion, premalignant changes are not a common feature of ovaries
prophylactically removed from women predisposed to develop female adnexal
carcinoma. In line with this, relatively few changes in the expression of proliferation
and differentiation related proteins have been observed. However, the increased
expression of bcl-2 and progesterone receptor in the inclusion cyst epithelium
of patients with a hereditary predisposition may reflect early disruption of
hormonal balance and growth control and is possibly indicative of premalignant
cell cycle disruption.
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Addendum to chapter 5
Carcinoma in situ arising in tubal metaplastic lining of
an inclusion cyst in a prophylactically removed ovary:
the missing link?
Jurgen M.J. Piek (1), René H.M. Verheijen (1),
Peter Kenemans (1), Paul J. van Diest (2).
Department of Obstetrics and Gynaecology, VU University Medical Center (1),
The Netherlands. Department of Pathology, University Medical Center Utrecht,
The Netherlands (2).
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Introduction 
Early events in serous ovarian carcinogenesis remain remarkably unknown.
Nevertheless, these tumours are the most common cause of death due to
gynaecologic malignancy and are diagnosed in 1.1 % of all women in Western
society (1-3). A significant factor in our lack of understanding how this type of
cancer develops is the absence of early clinical symptoms, resulting in detection
of disease at late stage, when tumour spread is no longer limited to the ovary (4).
Therefore, the precursor cell of these tumours remains a point of discussion (5-8),
although the ovarian surface epithelium (OSE) is commonly accepted as the tissue
of origin (9).
Women harbouring a mutation in one of the BReast CAncer 1 or BRCA2 genes are
at high risk to develop breast and / or female adnexal (ovarian and Fallopian tube)
carcinoma (10). Lifetime risk of serous female adnexal carcinomas in these women
could be as high as 60% (11;12). To reduce this risk of cancer, prophylactic bilateral
salpingo-oophorectomy is advised to women who have completed their families (13).
Therefore, prophylactically removed adnexes are a potential source for studies
into early steps of serous carcinogenesis, since premalignant and early malignant
lesions can be expected to be present in these tissues. Recently we reported on our
findings of premalignancies in prophylactically removed Fallopian tubes (8;14).
We showed that carcinoma precursor lesions are frequent in prophylactically
removed Fallopian tubes. In contrast, such premalignant lesions were rare in the
ovaries. However, in the tubal metaplastic lining of ovarian inclusion cysts, changes
in expression of cell cycle proteins and steroid receptors were noted (15), which
made us propose these cells as potential precursor cells for serous malignancy (8).
Here we present a case in which a carcinoma in situ (CIS) was present arising from
the tubal lining of an inclusion cyst in a prophylactic removed ovary from a BRCA1
mutation carrier, providing the first evidence for our hypothesis.
Case report 
A woman, 51 years of age, underwent prophylactic bilateral salpingo-oophorectomy
(pBSO) because of her BRCA1 (5382 ins C) germline mutation. Histological examination
of the resected specimen revealed numerous inclusion cysts in both ovaries.
These cysts were lined by epithelium showing the characteristics of Fallopian Tube
inner Surface Epithelium (TSE). Several of these cysts showed dysplastic changes
with multilayering of cells with atypical and hyperchromatic nuclei. In close
conjunction with these cysts, an area of a serous CIS was found with similar
morphology as in dysplastic tubal cysts (fig 1).
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Discussion
Our observation provides the first evidence that serous ovarian carcinomas can
arise from inclusion cysts that are lined by epithelial cells with a tubal-like
morphology through the usual hyperplasia-dysplasia-carcinoma sequence.
Two explanations as to the origin of these inclusion-cyst-lining-cells have been put
forward. The first one points towards the OSE as the ultimate tissue of origin (9).
These simple mesothelial cells get entrapped into the ovarian stroma after a follicle
rupture. Thereafter these cells undergo metaplastic transformation towards a
tubal phenotype, and can, possible under the influence of aberrant gene expression,
eventually undergo neoplastic transformation (fig 2). The second possible origin
are the actual tubal cells (8). It is postulated that TSE cells can exfoliate from
the Fallopian tube, can seed onto an ovarian stigma, and get entrapped to form the
lining of an inclusion cyst (fig 3).
Conclusion
In this case report we show a serous (pre)malignancy to arise in an ovarian
inclusion cyst lined with tubal-like epithelial cells. This case is thereby thus the
missing link for the hypothesis that these tubal-like cells can be the tissue of
origin of serous ovarian carcinomas.
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Figure 1: I: inclusion cyst lined by Tubal inner Surface Epithelium (TSE)-like cells.
II: Inclusion cyst lined by dysplastic cells.
III: Inclusion cyst lined by a serous carcinoma in situ (CIS).
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Figure 2: OSE (metaplasia) related serous ovarian carcinogenesis
Figure 3: TSE related serous ovarian carcinogenesis
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Chapter 6
Cultures of Ovarian Surface Epithelium from women with
and without a hereditary predisposition to develop female
adnexal carcinoma.
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Abstract
Aim: Conflicting evidence exists on whether in vivo morphological characteristics
can distinguish Ovarian Surface Epithelium (OSE) of ovaries obtained from women
with and without a predisposition to develop female adnexal (ovarian and Fallopian
tube) carcinoma. This study aims to detect differences in growth potential and
morphology that are maintained or specifically expressed in vitro.
Study design: Ovarian surfaces were scraped to retrieve OSE cells from 56 women
at hereditary high risk for female adnexal carcinoma, of whom 33 are BRCA1 and 4
are BRCA2 mutation carriers (Predisposed OSE, POSE) and from 26 women without
such risk (Non Predisposed OSE, NPOSE). Number of passages and total cell yield
until last passage, as well as morphology was compared between both groups.
To confirm morphology the expression of epithelial, mesothelial and fibroblast
markers was assessed.
Results: Both POSE and NPOSE cultures displayed similar growth potential and
morphology. The expression of epithelial markers cyto-keratins 7 and 8 was similar
between both groups. Only in cultures in which cells did not uniformly exhibit these
markers, the percentage of cells expressing these markers was significantly lower at
last passage when compared to the initial culture. In these latter cultures, cells that
were morphologically indistinguishable from fibroblasts were observed. Mesothelial
marker calretinin was expressed in 75% of cells of both POSE and NPOSE cultures
and correlates with cyto-keratins 7 and 8 expression. CA 125 expression was equally
low in POSE and NPOSE cultures (4.3%). Fibroblast markers FSM and vimentin
were expressed in 100% and collagen IV was expressed in 16% of cells in all cultures. 
Conclusion: OSE cells derived from women with a hereditary predisposition to
develop female adnexal cancer possess similar in vitro characteristics as OSE from
women without this predisposition. On basis of our results it seems advisable to
study only 100% cyto-keratins 7 and 8 positive OSE cultures, since contamination
of fibroblasts in some primary OSE cultures cannot be ruled out.
Introduction
The risk of ovarian carcinoma in western countries is 1.4% (1). In the European
community, about 26,000 new cases of epithelial ovarian cancer and approximately
17,000 ovarian cancer related deaths are diagnosed each year, putting ovarian
cancer forward as one of the most lethal cancers in women (2). Up to 10% of all
ovarian carcinomas is attributable to an inherited predisposition for breast or
ovarian/Fallopian tube (further denoted as female adnexal) cancer (3). Ovarian
cancer risk in this group can be as high as 45% (4). In up to 90% of these cases
germline mutations in either the BReast CAncer 1 (BRCA1) or the BRCA2 gene
can be detected (5,6). 
Although the pathogenesis of ovarian cancer is poorly understood, it is widely
believed that the layer of cells at the ovarian surface, the ovarian surface epithelium
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(OSE), is involved in the development of epithelial tumors of the ovary (7).
Some women predisposed to develop female adnexal carcinoma elect to undergo
prophylactic adnexectomy. To date, there is conflicting evidence whether or not
morphological characteristics in vivo can distinguish OSE from women at
high risk (8-15).
To gain more insight in growth potential and morphology of OSE in vitro,
we cultured OSE from women with a predisposition (Predisposed OSE, POSE)
to develop breast- and female adnexal carcinoma due to a BRCA1/2 gene mutation
and/or a family history of these tumors, and from women without such
predisposition (Non Predisposed OSE, NPOSE). To confirm morphological
assessment the expression of well-known epithelial, mesothelial and fibroblast
markers was assessed.
Methods
Material: institutional approval for this study was obtained before this study
from the scientific review boards as well as from the medical ethical committees
from the participating hospitals. Scrapings of the ovarian surface to harvest OSE
were acquired during prophylactic adnexectomy in women predisposed to develop
female adnexal cancer. Predisposition was defined as breast- and/or female
adnexal carcinoma in at least 3 first-degree family members in at least 2 consecutive
generations, as well as one patient with a diagnosis of breast or female adnexal
carcinoma before the age of 50. In this group BRCA1 and BRCA2 mutation
screening had been performed by the protein truncation test, followed by direct
sequencing as described in detail before (16,17). As controls, scrapings were
retrieved from patients without a family history of cancer, undergoing surgery not
related to ovarian or tubal pathology. Scrapings were performed in vivo from both
ovaries separately, by gently smearing the ovary three times with laparoscopic
scissors or Kocher forceps (18).
Cell culture: cells were cultured under standard conditions in 5 ml OSE medium
(18) [medium 199 with Earle’s salts (Sigma, St. Louis, USA) and MCDB 202
(Sigma), 1:1 ratio, with 15% Fetal Bovine Serum (FBS) and 25 µg gentamycin/ml
(Gibco, Taastrup, Denmark)] in 5 cm2 culture flasks (Nalge Nunc, Rochester, USA)
and incubated at 37°C, CO2 concentration at 5% and 95% air and left undisturbed
for 1 week. When confluent, the cells were trypsinized (5 mg/ml trypsin [Difco,
Franklin lakes, USA] and 2 mg/ml EDTA, dissolved in 95 ml phosphate buffered
saline solution) and seeded at a 1:2 split ratio. Quantitative assessment was
performed each passage (p) using a hemocytometer. This procedure was continued
until last passage, defined as no growth for one month.
At p1, half of the cells were allowed to grow on 8-well culture dishes (Beckton
Dickinson, Falcon 8 wells, 0.69 cm2/well, San Jose, USA). When confluent,
cells were fixed in 4% paraformaldehyde in PBS for 20 minutes and consecutively in
acetone (at -20°C) for 30 seconds. At last passage all cells were trypsinized as
described and suspended on 8 well culture dishes. Cells were allowed to adhere for
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at least 48 hours. Fixation was performed as described.
Morphology assessment: culture flasks were examined at 125 times magnification
using an inverted microscope (Zeiss ID03, Munich, Germany) at first and last
passage. For classification of cell cultures the criteria formulated by Auersperg et al.
(19) and Wong et al. (20) were applied in a modified fashion, that is, cultures with a
cobblestone pattern (Fig 1a) or flat cells (Fig 1b) were designated to contain
epithelium (mesothelium)-like cells. Atypical, or fusiform cells were designated
fibroblast-like cells (Fig 1c) and swirly cells were designated Fallopian tube
epithelium-like cells (Fig 1d).
Protein expression: an assessment was performed on 8 well culture dishes at p1
and at last passage for the epithelial markers cyto-keratins 7 and 8 (CAM 5.2,
Becton Dickinson, San Jose, USA). 
To further identify the phenotype of OSE cultures, on 5 NPOSE and 5 POSE
cultures that were less than 100%, and two NPOSE and two POSE that were 100%
cyto-keratins 7 and 8 positive at first and last passage, the following antibodies were
used: anti-cyto-keratins 7 and 8 (CAM5.2, Becton Dickinson, San Jose, USA),
anti-CA 125 (OC125, Dako, Glostrup, Denmark), mesothelial marker anti-calretinin
(Calret1, Dako), basement membrane marker anti-collagen type IV (CIV22, Dako),
Figure 1. A) Cobblestone epithelium-like cells in cultures of scrapings of the ovarian surface (125x).
B) Flat epithelium-like cells in cultures of scrapings of the ovarian surface (125x).
C) Fibroblast-like cells in cultures of scrapings of the ovarian surface (125x).
D) Fallopian tube-like epithelial cells (swirly cells) in cultures of scrapings of the
ovarian surface (125x).
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fibroblast markers Fibroblast Specific Marker (FSM, Dako) and anti-vimentin
(Bioprobe, Amstelveen, The Netherlands) and endothelial marker anti-CD31
(JC70, Dako). Immunohistochemistry was performed as described before (17).
Briefly, 8-well culture dishes were washed with phosphate-buffered saline (PBS)
between steps. Endogenous peroxidase activity was blocked with 0.03% hydrogen
peroxide in methanol for 10 minutes. Next, when applicable, antigen retrieval
was performed in 10mM citrate buffer at pH 6.0 at 100°C in a microwave oven.
After cooling down, the samples were pre-incubated with a solution of 10% normal
rabbit serum diluted in PBS with 0.05% saponin for 100 minutes. Eight well culture
dishes were then incubated with primary antibodies in PBS with 0.05% saponin
overnight at 4°C. The following day, dishes were exposed in sequence to biotinylated
rabbit anti mouse antibodies (1:500) diluted in PBS and 1% bovine serum albumin
for 60 minutes. Next, slides were exposed to Streptavidin Biotin Complex/HRP
(Dako) (1:200) diluted in PBS and 1% bovine serum albumine. The slides were
developed using 0.05% 3,3’-diaminobenzidine tetrahydrochloride dihydrate
containing 0.02% hydrogen peroxide. Slides were counterstained with hematoxylin
and mounted in DePeX mounting medium (BDH laboratory supplies, Poole, UK),
after dehydration. In negative controls the primary antibody was omitted and
PBS was used.
Scoring immunohistochemistry: cells grown on 8-well culture slides, were blindly
assessed at 200 times magnification. At least 200 cells were counted systematically
at random (21) by 2 independent observers (JP/JW). Results were compared and,
in case of disagreement, slides were reviewed until agreement was reached.
Statistical analysis: was performed by use of the Mann-Whitney, Wilcoxon Rank
sum and Pearson tests.
Results
Women: scrapings from 33 women with a proven BRCA1 mutation and from 4
women with a proven BRCA2 mutation were included in the study. Additionally,
19 patients at hereditary high risk to develop female adnexal carcinoma, without a
proven BRCA1 or BRCA2 mutation were included. A control group of 26 women
without a family history of cancer was assessed. There was no difference in age,
menarche, gravidity and parity between the groups (Table 1). 
Cultures: no difference between NPOSE and POSE was observed in either number
of successful cultures (defined as at least one passage in culture), mean cell yield
or total amount of passages in culture (Table 2). Morphology: no differences were
observed in morphology between NPOSE and POSE (Table 3). However, the
percentage of cells that appeared morphologically epithelial in culture (Fig 1a,b)
decreased significantly between p1 and last passage in both NPOSE (p<0.01) and
POSE (p<0.01). Fallopian tube epithelium-like cell colonies were detected in p1 of 2
NPOSE- and 3 POSE cultures (Fig 1d).
Protein expression: at p1 and last passage expression of cyto-keratins 7 and 8, 
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marker for epithelial cells (22) and mesothelial cells (23), was randomly assessed in
26 NPOSE and 44 POSE cultures (Table 4, Fig 2a). No difference was observed in
the expression of cyto-keratins 7 and 8 between NPOSE and POSE at p1 and last
passage. However, the percentage of cells expressing cyto-keratins 7 and 8
diminished significantly between p1 and last passage in both NPOSE (p<0.01) and
POSE group (p<0.01). Cyto-keratins 7 and 8 expression and epithelial morphology
at both p1 and last passage were highly correlated (p1: p<0.01, last passage: p<0.01). 
All 37 NPOSE and POSE cultures that were 100% cyto-keratins 7 and 8 positive at
p1 remained, however, 100% cyto-keratin positive until last passage. No difference
in total cell yield and passages in culture were observed between NPOSE (8 out of
28) and POSE (29 out of 64) (p=0.13) cultures which were 100% cyto-keratins 7 and 
8 positive in first and final passage (Table: 5).
To confirm OSE morphology, expression of, mesothelial, fibroblast and endothelial 
Table 2. Results of OSE cultures in patients without (controls) and with an inherited
predisposition for breast/ovarian/tubal cancer. The p-values are based on the
comparison between NPOSE and POSE subgroup. * based on family history
no proven mutation.
ovary NPOSE POSE
controls BRCA1 p-value BRCA2 p-value Hereditary* p-value
mutation mutation
# of successful cultures / number of scrapings
Left 17/25 22/33 0.98 2/4 0.78 9/16 0.64
Right 18/26 14/30 0.90 2/4 0.55 13/19 0.59
cell yield -x 106- (range)
Left 4.4 (0.2-11.9) 4.0 (0.1-8.5) 0.69 3.6 (0.3-6.9) 0.59 4.3 (0.8-14.2) 0.89
Right 5.4 (1.0-11.3) 4.8 (1.1-11.6) 0.27 3.6 (1.3-5.8) 0.59 4.0 (0.9-10.8) 0.77
passage (range)
Left 3.3 (1-9) 3.3 (1-7) 0.49 3.0 (1-5) 0.42 4.4 (1-20) 0.64
Right 4.7 (1-9) 3.7 (1-7) 0.30 2.5 (2-3) 0.19 4.2 (2-20) 0.53
Table 1. Age at OSE retrieval, age at menarche, number of pregnancies and of deliveries
in patients without (controls) and with an inherited predisposition for
breast/ovarian/tubal cancer. Listed are median values, between brackets the range.
* based on family history, no proven mutation (p-values all not significant).
controls BRCA1 mutation BRCA2 mutation Hereditary*
(n=26) (n=33) (n=4) (n=19)
Age (yrs) 46.2 (38-63) 45.1 (33-59) 49.4 (43-56) 51.2 (38-65)
menarche (yrs) 12.9 (11-16) 13.1 (11-16) 11 (12-15) 13 (11-17)
gravidity (#) 2.2 (0-6) 2.0 (0.4) 1.4 (0-3) 2.7 (0-4)
parity (#) 1.5 (0-3) 1.9 (0-4) 1.4 (0-3) 1.7 (0-4)
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markers was assessed in 7 NPOSE and 7 POSE cultures at p2 and last passage.
In 2 POSE and 2 NPOSE cultures 100% of cells expressed cyto-keratins 7 and 8 at
p2 and last passage. The other OSE cultures expressed cyto-keratins 7 and 8 in less
than 100% at both p2 and last passage, (Fig 2a, 3).
Expression of calretinin, a marker for mesothelial cells (24) was observed in
cytoplasm of OSE cells (Fig 2c, 3) and positively correlates with cyto-keratins
7 and 8 expression (p <0.01).
Table 5. Median cell yield and passages of OSE cultures from women without (NPOSE)
and with (POSE) a hereditary predisposition for breast/ovarian/tubal cancer that
were 100% positive for cyto-keratins 7 and 8 expression in first and final passage.
The p-values reflect the comparison between NPOSE and POSE.
NPOSE POSE p-value
Cell yield passages Cell yield passages Cell yield passages
*106 *106 *106
3.3 2.2 2.9 2.5 0.88 0.86
(0.1-7.5) (1-6) (0.1-7.2) (1-7)
Table 4. Median percentage of cyto-keratins 7 and 8 expression in cultures (range between
brackets) from patients without (NPOSE) and with (POSE) an inherited predisposition
for breast/ovarian/tubal cancer. The p-values are based on the comparison between
NPOSE and the POSE group. P1= at first passage, last = at last passage.
ovary NPOSE POSE p-value
p1 last p1 last p1 last
Left 76 67 98 77 0.36 0.97
(0-100) (1-100) (0-100) (0-100)
Right 97 64 82 76 0.14 0.92
(1-100) (3-100) (0-100) (0-100)
Table 3. Median percentage of epithelium-like cells (range between brackets) in OSE cultures
from patients without (NPOSE) and with (POSE) an inherited predisposition for
breast/ovarian/tubal cancer. The p-values are based on the comparison between
NPOSE and the POSE subgroup. P1= at first passage, last = at last passage,
* based on family history, no proven mutation.
ovary NPOSE POSE
controls BRCA1 p-value BRCA2 p-value Hereditary* p-value
mutation mutation
p1 last p1 last p1 last P1 last p1 last p1 last p1 last
Left 89 67 89 73 0.69 0.79 82 63 0.62 0.88 84 51 0.60 0.49
(5-100) (0-100) (25-100) (0-100) (50-100) (40-100) (50-100) (0-100)
Right 87 70 76 56 0.96 0.34 99 98 0.53 0.19 77 75 0.32 0.38
(10-100) (0-100) (0-100) (1-100) (99-100) (95-100) (2-100) (0-100)
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CA 125, a mucin-like antigenic determinant (25), was expressed in round, flat cells
(Fig 2d, 3). Expression of CA 125 was significantly reduced at last passage when 
compared to p1 in both NPOSE and NPOSE (p=0.02) and has been found to
correlate positively with cyto-keratins 7 and 8 expression (p=0.02).
At p2 and last passage 100% of all cells in all NPOSE and POSE cultures expressed
FSM, which identifies prolyl 4-hydroxylase activity (26), and vimentin, an
intermediate filament protein (27).
The expression of collagen type IV, a basement membrane protein (28), was
observed in 18% of all cells, specifically in those that possessed a round-flat
phenotype and within vacuoles in the cytoplasm of these cells (Fig 2b, 3). No
correlation between cyto-keratins 7 and 8 and collagen IV was observed (p=0.23).
No expression of CD31, a pan-endothelial marker (29) was observed in OSE.ˆ
Discussion
In this study both OSE derived from women with and without an inherited
predisposition to develop female adnexal cancer appeared to be capable of
proliferation in vitro, with no differences in growth potential, morphology and 
studied markers between both groups.
Figure 2. A) Keratins 7 and 8 expression in cultures of scrapings of the ovarian surface (200x).
B) Collagen type IV expression in cultures of scrapings of the ovarian surface (200x).
C) Calretinin expression incultures of scrapings of the ovarian surface (200x).
D) CA 125 expression in cultures of scrapings of the ovarian surface (200x).
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These results support our and other recent in vivo studies in which no differences
in morphology of ovaries from women with and without an inherited predisposition to
develop female adnexal carcinoma could be distinguished (11,14,30).
This contrasts with a study by Dyck et al. in which POSE cultures appeared to remain
phenotypically more epithelial when compared with NPOSE cultures (31).
In our experience it is easy to overlook single cyto-keratin 7 and 8 negative cells within
cultures apparently 100% positive for these cyto-keratins. Our experiments show
that only if cultures contain initially cyto-keratins 7 and 8 positive cells and also
cyto-keratin 7 and 8 negative, fibroblast-like, cells a change towards a fibroblast-like
culture is observed (Fig 4). This alteration is most probably due to contaminating
fibroblast overgrowth, as has been suggested before for OSE cultures (32) and other
primary epithelial cell cultures (33-38), rather than constituting a conversion of
cyto-keratins 7 and 8 positive epithelial cells into fibroblast-like cells. This implies that
for future studies only 100% cyto-keratins 7 and 8 positive OSE cultures should be
utilized. When analyzing growth potential and morphology of these latter 
cultures also no differences were observed between NPOSE and POSE.
To be able to relate our study with other studies (31) we used markers, which
substantiate morphology. Vimentin, (39), and Fibroblast Specific Marker appear
to be stable markers for OSE, but also for fibroblasts (26,27) in culture.
These markers are thus not suitable to distinguish between OSE and fibroblasts
in culture. Vimentin is found in most differentiating cells, moreover it is expressed 
in OSE in vivo (7). The expression of FSM in OSE indicates that these cells possess 
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p last                                p last
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p last                                p last
NPOSE p2   NPOSE         POSE p2      POSE
p last                                p last
A. cyto-keratins 7 and 8 expression
p2. p=0.38, p.last, p=0.36
B. calretinin expression
p2, p=0.32, p last, p=0.62
C. collagen IV expression
p2, p=0.71, p last, p=0.71
D. CA125 expression
p2, p=0.45, p last, p=0.45
Figure 3. Expression of A) cyto-keratins 7 and 8, B) calretinin, C) collagen type IV, and
D) CA125 in OSE cultures from women without (NPOSE) and with (POSE) a
hereditary predisposition for breast/ovarian/tubal cancer. Depicted are the median
percentage of positive cells and range. P2= at second passage, p last= at last
passage. The p-values reflect the comparison between NPOSE and POSE.
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proline 4-hydroxylase activity, which catalyses the formation of 4-hydroxyproline
in collagens (40). Expression of collagen IV was observed in cytoplasm and in
vacuoles of round, flat cells. This indicates that these specific cells are capable of
producing basement membrane proteins in vitro (41).
Cytoplasmatic calretinin expression was observed in all OSE cultures that
morphologically and histochemically consisted of epithelial cells. Calretinin
therefore could be a potential marker, to distinguish OSE cells from contaminating
cells, such as fibroblasts. Furthermore, calretinin expression is consistently observed
in normal mesothelial cells, but not in serous adenocarcinomas (42). This suggests
that during neoplastic progression of OSE, calretinin expression is down-regulated.
The CA 125 protein is normally expressed in the Fallopian tube (43), but is also
commonly expressed in ovarian carcinomas. In the management of these tumors
CA 125 is utilized as a tumor marker (44). CA 125 was expressed in few cells of all
OSE cultures, without differences between POSE and NPOSE. Thus, during OSE
related carcinogenesis CA 125 must be up regulated. Alternatively, only these CA
125-expressing cells can be responsible for the development of ovarian carcinomas.
Furthermore, our findings contrast with a study in which POSE appeared to express
CA 125 in a higher percentage of cells (45). A possible explanation is that OSE
cells utilized within the latter study harbored different BRCA mutations than the
OSE cells used in this study. However, this seems unlikely since we did not observe
differences between OSE cultures derived from women with a hereditary
predisposition to develop female adnexal carcinomas with and without a detected
BRCA mutation.
Figure 4. First passage culture derived from the ovarian surface. Top right, fibroblast-like
cells. Bottom left, cobblestone epithelium-like cells (200x).
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Previous studies demonstrated right ovaries to be more prone to epithelial
cancer development than the left (46,47). Although, other studies were not able
to substantiate this observation (48,49). Since we did not detect differences in
phenotype of cultures derived from either left or right ovary, our data support the
latter observation.
Fallopian tube-like epithelial cell colonies were observed in p1 of 5% of all cultures
of both NPOSE and POSE (Fig. 5). These cells could be metaplastic, as suggested
by others (20), but could also be Fallopian tube epithelial cells that have been
grafted upon the ovarian surface (17,50,51). This latter implantation theory is
plausible, since the ovary is in close contact with the tubal fimbriae and additionally,
fimbriae make sweeping movements over the ovarian surface around the time of
ovulation (52). Furthermore, these Fallopian tube epithelium-like cells possess a
morphology that exactly resembles the morphology of Fallopian tube inner surface
epithelial cells in culture (53,54). It has been proposed that these Fallopian tube
inner surface epithelial cells can become included within the ovary, lining ovarian
inclusion cysts (30).
In conclusion, OSE cells derived from women with a hereditary predisposition
to develop female adnexal cancer possess similar in vitro morphology as OSE from
women without this predisposition. On basis of our results it seems advisable to
study only 100% cyto-keratins 7 and 8 positive OSE cultures, since contamination
of fibroblasts in some primary OSE cultures cannot be ruled out.
Figure 5. First passage culture derived from the ovarian surface. Top right, cobblestone
epithelium-like cells. Bottom left, Fallopian tube epithelium-like cells (200x).
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Chapter 7
BRCA1 and p53 protein expression in cultured Ovarian
Surface Epithelial cells derived from women with and with-
out a BRCA1 germline mutation.
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Abstract
Aim: Early genetic hits and gene expression alterations leading to hereditary
ovarian carcinoma are largely unknown, as yet. However, the human Ovarian
Surface Epithelium (OSE) is considered the tissue of origin of at least a subset of
these tumours. Therefore, OSE cell cultures derived from women harbouring BRCA1
germline mutations could be a potential model to study such initial steps. Since
previous in vivo studies indicate loss of the BRCA1 wild type allele and TP53
mutations to be early events in hereditary ovarian carcinogenesis, we assessed
the protein expression of these genes in cultured OSE cells.
Study design: Thirty-two OSE cultures derived from women harbouring a BRCA1
mutation (Predisposed OSE [POSE]) and ten cultures from women without a
cancer predisposition (Non Predisposed OSE [NPOSE]) were grown under standard
conditions. Immunocytochemistry was performed to assess the expression of
BRCA1- and p53 proteins. Ki67 immunocytochemical expression was assessed to
determine possible differences in cell cycle status between the two groups.
In addition, to study whether wild type p53 was expressed, induction of p53 by
cis-platinum was assessed by Western blot.
Results: Both the BRCA1 and p53 proteins were expressed in OSE in vitro.
No differences between POSE and NPOSE were observed in the expression of
BRCA1 (p=0.25), p53 (p=0.07) or Ki67 (p=0.81). In POSE and NPOSE, p53 was
induced by cis-platinum to a similar extent.
Conclusion: Our study indicates no obvious differences in the expression of both
BRCA1 and p53 proteins when comparing POSE with NPOSE. These findings
suggest the absence of losses of the wild type BRCA1 and p53 genes in the studied
OSE cultures.
Introduction
Women harbouring BRCA1 germline mutations are predisposed to develop breast
and female adnexal (ovarian and Fallopian tube) carcinomas (1,2). Little is known
on initial genetic steps leading to hereditary ovarian carcinoma. However,
carcinogenesis and therefore ovarian carcinogenesis, is considered to be a multistep
process with loss of tumour suppressor genes and gains of oncogenes (3).
Recent studies indicate that loss of the BRCA1 wildtype allele and loss of p53
alleles can constitute such initial steps in hereditary ovarian carcinogenesis (4,5).
Ovarian Surface Epithelial (OSE) cells are considered the cell of origin of at least a
subset of ovarian carcinomas (6). Therefore, cultures of these epithelial cells derived
from women harbouring BRCA1 germline mutations can serve as potential models
to study (hereditary) ovarian carcinogenesis. To assess whether loss of expression
of the tumour suppressor genes BRCA1 and p53 are present in a panel of both
Non cancer Predisposed OSE (NPOSE) and cancer Predisposed OSE (POSE)
cultures we determined the expression of these proteins by immunocytochemistry.
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Furthermore, to assess whether wildtype p53 was expressed cis-platinum induction
of p53 was studied by Western blot.
Methods
Material
Institutional approval for experimentation with human tissues was obtained
before this study from the scientific review board, as well as from the medical ethical
committees from the participating hospitals. Scrapings of the ovarian surface to
harvest OSE were acquired during prophylactic adnexectomy in women harbouring
a BRCA1 mutation. Mutation screening had been performed by the protein
truncation test, followed by direct sequencing as described in detail before (7).
As controls, scrapings were retrieved from women without a family history of
cancer, at interventions not related to ovarian or tubal pathology.
Cell culture
Only cultures with a 100% epithelial phenotype at senescence, defined as 100%
keratins 7 and 8 positive were utilized (8). Passage 1 cells, which were stored in
liquid nitrogen, were taken into culture by suspension in 5 ml OSE medium
(medium 199 with Earle’s salts [Sigma, St. Louis, USA] and MCDB 202 [Sigma, St.
Louis, USA], 1:1 ratio, with 15 % Fetal Bovine Serum and 25 µg gentamycin / ml
[Gibco, Taastrup, Denmark]) in 5 cm2 culture flasks (Nalge Nunc, Rochester, USA),
and cultured in an incubator (Nuaire, Plymouth, USA) at 37°C, CO2 concentration
at 5 %. When confluent, the cells were trypsinized (5 µg/ml Trypsin [Difco, Franklin
lakes, USA] and 7 mM EDTA dissolved in phosphate buffered saline solution
(Braun, Melsungen, Germany). One half of the passage 2 cells was sub-cultured in 5
cm2 culture flasks (Nalge Nunc) until senescence (defined as no growth for one
month), at which time point cells were trypsinized and allowed to adhere to 8 well
culture dishes (Falcon 8 wells, 0.69 cm2/well, Beckton Dickinson, San Jose, USA)
for 24 hours. The other half of the passage 2 cells was re-suspended in 8 well culture
dishes and allowed to grow for 48 hours in OSE medium.
Immunocytochemistry
After 48 hours on 8 well culture dishes, cells were fixed in 4% paraformaldehyde
(Merck, Hohenbrunn, Germany) in phosphate buffered saline solution for 20
minutes and subsequently in ice-cold acetone for 30 seconds. Immunocytochemistry
was performed according to manufacturer’s recommendations with mouse
monoclonal antibodies, to the following proteins: BRCA1 (Ab-1, Oncogene Research
Products, Cambridge, USA). P53 (BP53-12, Bioprobe, Amstelveen, The Netherlands)
and Ki67 expression (MIB1, Immunotech, Marseille, France). Cyto-keratins 7 and 8
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(CAM 5.2, Becton Dickinson, San Jose, USA) expression was studied at senescence.
Scoring protein expression with immunocytochemistry: cells grown on 8 wells
culture dishes were evaluated semi quantitatively by 2 different observers 
JMJP, JW), applying a modified histoscore (=cytoscore) technique (9).
Briefly, percentage of negative (score 1), weakly positive (score 2), positive (score 3)
and strongly positive (score 4) nuclei (fig:1) was calculated by scoring at least 200
nuclei systematically at random applying a counting raster. In case of inequality
of percentages between observers, dishes were reassessed until agreement was
reached. Statistical analysis was performed by the Mann-Whitney and Kruskal-
Wallis tests.
Western blot
The expression of p53 was assessed in ten NPOSE cultures and ten POSE cultures
which were cultured at p2, for 15 hours in normal OSE culture medium in presence
and absence of 40 µM Cis-platinum (Platinosin 10mg/ml, Pharmachemie B.V.,
Haarlem, The Netherlands). Western blot analysis was performed as described
before (10,11). Briefly, cell extracts from T25 flasks (Nalgene Nunc) were prepared in
either 250 µL Laemmli buffer [2% SDS (Sigma, St. Louis, Mo, USA), 55 mM TRIS
(Sigma) pH 6.8, 9% glycerol (Sigma), 50 µL/ml of a saturated Bromo phenolblue
solution (Sigma), 75µl/ml beta-mercapto ethanol] or 250µl TNE buffer [ 250 mM
NaCL, 50mM TRIS (Sigma) pH 7.5, 0.1% Triton X-100 (Sigma) and 5mM EDTA
(Sigma) pH 8.0] with added protease inhibitors (P2714, Sigma). Total protein
concentration was determined by the Bradford method. Seventy µg total protein was
Figure 1: Cytoscore quantification technique for the expression of the Ki67 protein.
A) absence of nucleic immunocytochemical staining for Ki67.
B) Weakly positive nucleic staining for Ki67.
C) Positive nucleic staining for Ki67.
D) Strong positive staining for Ki67.
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used on 10 % acrylamide gels, as described previously (11). Proteins were separated
at 100 volts. Blotting was performed in blot buffer [25 mM TRIS (Sigma), 192 mM
glycin (Sigma) and 20% methanol] overnight at 100mA. Detection of proteins was
performed with mouse monoclonal antibodies raised against p53 (DO 7, Novocastra,
Newcastle Upon Tyne, United Kingdom) and beta-tubulin (18-0093, Zymed
Laboratories Inc., San Fransisco, USA). HRP conjugated goat anti mouse IgG and
IgM (Biosource international, Camarillo, USA) was used as a secondary antibody.
Cruz Markers (Santa Cruz Biotechnology inc., Santa Cruz, USA), including
appropriate secondary antibodies (sc-2031, Santa Cruz Biotechnology Inc.), were
used as molecular weight standards. Chemiluminescent HRP detection (Amersham
biosciences, Little Chalfont, United Kingdom) was performed according to
manufacturers recommendations.
Results
To study the expression of the BRCA1 and the p53 genes at the protein level,
immunocytochemistry was performed at passage two on 32 cultures from women
carrying a BRCA1 mutation and ten cultures from women without a hereditary high
risk on cancer. Table one represents results from the immunocytochemistry,
acquired by the cytoscore technique.
The BRCA1 antibody (figure 2a) used in this study, is directed against the
N-terminal part of the protein (12) in order to assure staining of both wildtype
and possible expressed mutated gene products. No significant difference in the
cytoscores of BRCA1 (p=0.25) was observed between NPOSE and POSE.
The p53 antibody (figure 2b) used in this study, is directed against amino acids
20-25 and 37-45 of the p53 protein (13). No significant difference in the cytoscores
of p53 (p=0.07) was observed between NPOSE and POSE.
In order to study possible cell cycle differences between cultures, we assessed
the cytoscore of Ki67, which is a protein that is expressed in all cell cycle phases
except G0 (14). No significant difference was observed in the cytoscores between
NPOSE and POSE (p=0.81), indicating that no cell cycle differences between NPOSE
Table 1. Cytoscore for Ki67, BRCA1 and P53. Median expression of indicated proteins using
the cytoscore technique (see materials and methods section). Between brackets, the
range is indicated. The p-value indicates the comparison of cytoscores, derived from
indicated proteins, between NPOSE and POSE.
NPOSE POSE p-value
Ki67 225 (131-295) 228 (100-296) 0.81
BRCA1 130 (100-180) 144 (100-263) 0.25
P53 275 (182-304) 250 (100-305) 0.07
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and POSE were present. However, a significant correlation was observed between 
the cytoscores of Ki67 and BRCA1 (NPOSE, p<0.01, POSE, p<0.01) and between
the cytoscores of Ki67 and p53 (NPOSE, p<0.01, POSE, p=0.03).
Western blot
Figure 3 depicts representative examples of a Western blot experiment.
No differences between NPOSE and POSE could be detected in the expression
of p53. Furthermore, induction of p53 in NPOSE and POSE by cis-platinum
was similar.
Discussion
No apparent difference in BRCA1 protein expression between NPOSE and POSE
was observed, as detected by immunocytochemistry with the cytoscore technique.
Knudson’s two hit hypothesis implies that loss of two alleles of a tumour
suppressor gene has to occur in order to inactivate the function of this gene (15).
This hypothesis implicates that loss of gene expression is more likely to be observed
in POSE than in NPOSE, since in mutation carriers only one allele has to be lost,
the other allele being already mutated.
Recently it has been demonstrated in lymphoblasts of BRCA1 mutation carriers,
that only mutations of the BRCA1 gene either in the last exon or very close to the
translation initiation codon can lead to detectable transcripts of mRNA.
The majority of mutations in the BRCA1 gene resulted in increased degradation
of BRCA1 mRNA and therefore probably severely reduced mutated BRCA1 protein
production (16). Since we used an antibody raised against the N-terminal part of
the BRCA1 protein, we anticipated that losses of the wild type BRCA1 allele would
have resulted in abrogation of normal BRCA1 proteins and loss of positive
immunocytochemistry in most POSE cultures. In our POSE cultures, therefore,
the wildtype BRCA1 allele likely still exists. However, in some POSE but also some 
Figure 2. Immunocytochemistry of OSE cultures. Representative examples of BRCA1 (A)
and p53 (B) expression in OSE cultures.
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NPOSE cultures, no BRCA1 expression was observed. In all these cultures, Ki67
expression was low as well, indicating that most cells were in G0 phase, during
which BRCA1 expression is expected to be absent (17). However, we cannot rule out
that in a minority of POSE cultures, but also in some NPOSE cultures, loss of the
wildtype BRCA1 gene had occurred. Nevertheless, since the phenomenon of no
detectable BRCA1 protein levels was observed both in POSE and in NPOSE, it seems
most likely that the cells still have at least one wild type allele, but that expression
was below the detection levels of the utilized technique.
Mutations in the TP53 gene are common in a wide variety of carcinomas. Werness et
al. showed that loss of TP53 is an early step in hereditary ovarian carcinogenesis (4).
Our study indicates, that immunocytochemical p53 expression is similar in NPOSE
and POSE cultures, however, a trend towards lower p53 expression in POSE was
observed. This is counterintuitive, since in case of p53 mutation a higher expression
should have been observed, therefore we verified whether wildtype or mutated p53
protein was produced. We studied p53 induction by cis-platinum in both NPOSE
and POSE cultures. In all cases and controls, similar induction of p53 was observed,
which suggests expression wild type p53. In our study, p53 expression highly
correlated with Ki67 expression. This was also observed before for human urothelial
and oesophageal cell cultures (19,20). In these studies expression of wildtype p53
was cell cycle dependent and high. It could therefore well be that our observations
for p53 represents a physiological response of OSE cells to the in vitro environment.
In conclusion, our study indicates no obvious differences in the expression of both
BRCA1 and p53 proteins between POSE and NPOSE. The findings suggest the
absence of losses of the wild type BRCA1 and p53 genes in the studied OSE cultures.
Acknowledgements
The authors thank Paul J. van Diest for reviewing this article and Rob Verstraeten
for his kind help with the statistical analysis. Furthermore, we thank Anemiek van
Maldegem and Rebecca de Wit for their kind help with the western blot procedure. 
Figure 3. Representative western blot results for p53 (53 kD) and beta-tubulin (50 kD). C- =
NPOSE without cisplatinum, c+ = NPOSE with cis-platinum, M- = BRCA1 mutated
OSE without cis-platinum, M+ = BRCA1 mutated OSE with cis-platinum.
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Chapter 8
Conclusions, general discussion and future perspectives
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Conclusion
In women at hereditary high risk to develop female adnexal carcinomas, only the
serous histotype is related to this predisposition. The Ovarian Surface Epithelium
(OSE), the commonly proposed precursor of ovarian serous carcinomas, appeared to
be remarkably inert as premalignant changes in OSE of prophylactically removed
ovaries in patients at hereditary high risk of serous female adnexal cancer were rare.
In contrast, the Tubal inner Surface Epithelium (TSE) in prophylactic resections
frequently harboured dysplastic changes as well as changes on the level of Ki67,
p21 and p27 protein expression. Further, the tubal lining of ovarian inclusion cysts
often showed phenotypic changes in contrast with the OSE lined inclusion cysts.
The only pre-malignancy which was found in the ovaries of these patients originated
in a cyst within the ovarian stroma lined with serous and ciliated cells that resemble
the morphology of TSE. Therefore, we propose TSE of the Fallopian tube and TSE-
like cells lining ovarian inclusion cysts as an important tissue of origin of serous
female adnexal carcinomas.
General discussion
The above-mentioned conclusions are substantiated by the following observations.
Firstly, our study on the morphology of hereditary related intraperitoneal
carcinomas shows that only the serous subtype is found in women with a BRCA1
or BRCA2 germline mutations (1). One comprehensive study by Shaw et al. is in
agreement with our observation (2). Secondly, our studies on the prevalence of
(pre)malignancies in ovaries and Fallopian tubes of women at hereditary high risk
of serous female adnexal carcinomas show that premalignancies are not common in
the ovary (3), but on the contrary a substantial part of prophylactically removed
Fallopian tubes harboured premalignant lesions underlining the potential of TSE for
malignant derailment (4). This malignant potential of TSE coincides with changes
in the expression of cell cycle related proteins Ki67, p21 and p27. 
Because the dataset in the above-mentioned studies was rather small, we are now
in the process of expanding this study. In our second, more comprehensive study
comparing the prevalence of (pre) malignant lesions in Fallopian tubes (n=44) and
ovaries (n=87) of women at hereditary high risk to develop breast and female adnexal
carcinomas and those of a control group, 37% of women at risk harboured truly
dysplastic lesions -defined as a multilayer of cells with round to oval nuclei,
hyperchromasia and/or atypia of nuclei- within the Fallopian tube, versus none
in the control group. It was also noted, that premalignant changes in the ovary
occurred only once in a high-risk patient. This concerned a serous ovarian
carcinoma in situ (CIS) arising from an inclusion cyst lined by cells with a tubal
phenotype. Studies by others also showed occult Fallopian tube carcinomas in
women at hereditary high risk for breast / intraperitoneal carcinomas (5-8).
Additionally, malignant cells were present female adnexal washings of women with
a family history of breast / female adnexal epithelial cancer whom underwent a
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prophylactic Bilateral Salpingo Oophorectomy (pBSO) procedure, and appeared to
have occult tubal carcinomas (9), indicating that seeding of malignant tubal cells is
an early event in tubal carcinogenesis. 
Thirdly, the innocuous character of OSE derived from women at hereditary high
risk for serous intraperitoneal carcinomas was supported by the in vitro studies
discussed in this thesis. Comparison of culture characteristics of OSE derived from
women with and without a hereditary high risk on serous female adnexal
carcinomas showed similar results for both groups (10). Even BRCA1 protein
expression appeared to be statistically not different in our studies (this thesis).
Therefore, a substantial proportion of serous intraperitoneal hereditary cancers
may actually derive from TSE. There is reason to believe that the frequency of
hereditary Fallopian tube carcinomas is underestimated, as many serous cancers
present at late stage of disease when it is impossible to distinguish ovarian from
Fallopian tube carcinoma. This has also been described for sporadic Fallopian tube
carcinomas (11;12). Further, a significant proportion of serous ovarian cancers
may derive from the frequently occurring tubal phenotype epithelium lining ovarian
inclusion cysts (13).
Future perspectives
Although the results of this thesis have put the tubal surface epithelium and the
tubal phenotype lining of ovarian inclusion cysts within the focus of BRCA1/2
related female adnexal oncogenesis, clearly not all issues have been solved and
further research is necessary.
Oncogenesis
First, the "incessant ovulation theory" postulates that repeated minor traumata
to OSE as well as repeated exposure of OSE to the estrogen rich viscous fluid
eventually leads to malignant derailment of this tissue (14). This hypothesis is
supported by the observation that in patients denied the physiological ovarian rest
periods, afforded by pregnancies, a higher incidence of ovarian cancer has been
reported. However, our data and those by others suggest that for hereditary serous
female adnexal carcinogenesis, cells with a tubal phenotype, lining ovarian inclusion
cysts, are a more likely precursor than OSE. The question whether this lining is
derived by true metaplasia or seeding of TSE cells to the ovary during fimbrial
movement over the ovary needs to be addressed (15). 
Further, the proposed precursor role of tubal phenotype cells does not necessarily
contrast with the "incessant ovulation theory". Less ovulation will result in less
movement of the Fallopian tube on the ovarian surface (16;17), possibly resulting
in less TSE seeding on the ovarian surface and also on the ovulation wound. This, in
time, might lead to creation of fewer TSE lined ovarian inclusion cysts, which are
believed to be predilection spots for ovarian carcinogenesis (18).
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Additionally, retrograde menstrual blood flow, which is blood that enters the
abdominal cavity during menstruation also carrying endometrial and tubal cells,
is diminished (19). In fact, oral contraceptives (20), which also increase the ovarian
rest periods, and tubal ligation (21) both showed a decreased risk on intraperitoneal
cancers in women at high hereditary risk to develop breast / female adnexal
epithelial cancers, both substantiating the "incessant ovulation theory" but also
the "exfoliation and implantation (Autumn) theory". 
TSE possesses a wide variety of hormone receptors, and changes in mitotic activity
during the menstrual cycle have been observed in TSE (22). In order to integrate the
"incessant ovulation" and the "exfoliation and implantation" theory animal studies
have to be designed. The domestic hen might be a valuable experimental animal
(15;23).
Oncogenetic pathways need to be clarified. Data of this thesis show altered
expression of some common carcinogenesis related cell cycle proteins and hormone
receptors in TSE of prophylactically removed adnexes in women at hereditary
high risk to develop serous intraperitoneal carcinomas (4). This indicates that in
morphologically normal TSE, deregulation of these proteins is already present and
thus be an early event in carcinogenesis, as has been described for breast tissue of
BRCA1 /2 germline mutation carriers (24). Future studies will have to focus on
the pathways in which these proteins play a role.
Further, we have studied genetic gains and losses in primary serous Fallopian tube
carcinomas by array-CGH (25). The patterns of gains and losses were remarkably
similar in a set of 14 Fallopian tube carcinomas. A conventional CGH study by
Pere et al. already indicated that serous ovarian and Fallopian carcinomas show
remarkably similar patterns of gains and losses (26). Therefore, it is interesting to
perform array-CGH on stage matched primary serous ovarian carcinomas and
compare the data to Fallopian tube cancers. If the cell of origin of these carcinomas
is TSE instead of OSE, clustering of both Fallopian tube and ovarian carcinomas
together is anticipated. 
Additionally, performing Multiplex Ligatable Probe Amplification (MLPA) (27)
on laser microdissected dysplastic lesions, with probes designed on loci that are
frequently lost or gained in tubal carcinomas by array-CGH, might reveal copy genes
involved in malignant derailment of TSE, eventually leading to insight into serous
tubal carcinogenesis.
Since only scant information is available on in vitro characteristics of TSE,
morphological and molecular TSE culture characteristics derived from women
with and without a hereditary predisposition to develop breast / female adnexal
serous carcinomas should be compared and described. 
Furthermore, in this thesis we demonstrate, in contrast to previous studies by one
other group (28), that in vitro properties of cultures of OSE derived from women
with and without a hereditary predisposition for breast / female adnexal carcinomas
are identical with respect to the features investigated. A possible explanation for
this discrepancy is that cultures used in our studies were 100% epithelial -defined as
keratins 7 and 8 expression- whereas other studies could have been biased by
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fibroblast contamination in the cultures (10). Next step in our research project
will be the assessment of expression of both wild-type and mutated BRCA1 mRNA
in OSE cultures. 
Clinical implications
The commonly accepted prophylactic regimen for women at hereditary high risk
for serous female adnexal carcinomas is removal of both ovaries and Fallopian tubes
after one has completed her family. This procedure implicates that these women
become postmenopausal directly after the prophylactic surgery. This causes well
known short- and long-term complications in these women, like hot flushes,
headaches, sterility and bone demineralisation. If hereditary related serous
carcinomas do, to a large extent, not primarily arise in the ovary but in the Fallopian
tube, prophylactic removal of only both Fallopian tubes might be sufficient to
achieve a significant reduction of risk on serous intraperitoneal carcinomas.
A problem that remains to be resolved is that during pBSO procedures the uterine
intramural part of the Fallopian tubes remains in situ. Whether this part of the
Fallopian tube is also prone to undergo carcinogenesis is unknown, therefore
research should be performed on this topic.
Lastly, to facilitate consciousness by both patients and clinicians on the risk of
cancers in patients with BRCA1 and BRCA2 gene mutations, we urge to alter the
nomenclature from women at hereditary high risk of breast and ovarian
carcinomas" to "women at hereditary high risk to develop breast and serous female
adnexal carcinomas".
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Summary
This thesis focuses on ovarian carcinogenesis. On a yearly basis this disease occurs
in about 1500 Dutch women. In most cases the disease is advanced, causing a 5-year
survival of 30%. Another disadvantage of the detection of this disease at late stage
is that not much is known about initial steps in ovarian carcinogenesis.
The BReast CAncer 1 and BReast CAncer 2 genes were detected in 1994 and 1995
respectively. Women harbouring a germline mutation in one of these genes have
a lifetime risk of up to 40% to develop ovarian carcinoma. A strategy to reduce
this risk is removal of both ovaries and Fallopian tubes. Research on these
prophylactically removed female adnexes could potentially give insight into ovarian
carcinogenesis, since carcinoma precursor lesions are expected in these specimens.
Chapter 2
Intraperitoneal serous adenocarcinoma; a critical appraisal of three hypotheses
on its aetiology. From the literature, which deals with ovarian carcinogenesis,
two theories have been postulated regarding the cell of origin of these tumours.
In this chapter we propose yet another theory. 
The first hypothesis puts the mesothelial lining of the ovary, the Ovarian Surface
Epithelium (OSE) forward as cells of origin of ovarian carcinoma. According to this
hypothesis ovarian mesothelial cells get entrapped within the ovarian stroma after
a follicle rupture. After inclusion these cells undergo metaplastic changes, in most
cases in the direction of Fallopian tube epithelium (serous cells). Next step is
thought to be a dysplastic change and eventually these cells can become malignant.
Secondly, the secondary Müllerian system is put forward as originator. This system
contains remnants of the embryologic Müllerian ducts. These ducts normally form
the endocervical canal, the endometrium and the Fallopian tubes. Sometimes the
cranial part of these duct do not totally regress, forming the abberant secondary
Müllerian system. It is hypothesized that these embryological multipotent cells can
differentiate into all tissues derived from this system (Fallopian tube, endometrium
and endocervix), and finally can become (pre)malignancies.
Next to these hypotheses, we hypothesize a third theory regarding serous ovarian
carcinogenesis. During the ovulatory process the fimbrial part of the Fallopian tube
moves across the ovarian surface. Tubal cells do exfoliate and get entrapped within
the ovarian stroma. After this inclusion (pre)malignancies can arise.
Chapter 3
Histopathological characteristics of BRCA1- and BRCA2 associated intaperitoneal
cancer, a clinic bases study. Intraperitoneal cancers that arose in women visiting our
outpatient and their family were recorded. In 42 families with a BRCA1 or BRCA2
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mutation 62 mutation carriers with intraperitoneal malignancies were described.
Compared with a reference group, which was obtained from the Dutch cancer
registry, serous tumours are the predominant type of tumours found in the
hereditary set. Primary Fallopian tube carcinoma was detected three times more
often in this hereditary group than in the reference group.
Chapter 4
Dysplastic changes in prophylactically removed Fallopian tubes of women
predisposed to developing ovarian cancer. The frequency of (pre)neoplastic lesions
in Fallopian tubes of women with and without a hereditary determined risk on
female adnexal carcinomas was assessed. Also the expression of some common cell
cycle- and differentiation related proteins was studied. In 50% of Fallopian tubes
from women harbouring a hereditary high risk, dysplastic changes were detected,
versus none in the control group. The expression of proliferation- and
differentiation related proteins Ki67, p21 and p27 was increased in the hereditary
group, when compared to the control group.
Chapter 5
Expression of differentiation and proliferation related proteins in epithelium of
prophylactically removed ovaries from women with a hereditary female adnexal
cancer predisposition. The frequency of (pre)neoplastic lesions in ovaries from
women with and without a hereditary determined high risk on female adnexal
tumours was studied. Moreover, the expression of cell cycle- and differentiation
related proteins was assessed. No (pre)neoplastic lesions were detected in either
groups. The expression of estrogen-alpha receptor, p21 and p27 was significantly
higher in inclusion cyst epithelium than in the ovarian surface epithelium of both
cases and controls. Furthermore, the expression of bcl-2 and PR was higher in
inclusion cysts of cases in comparison with ICE of controls.
Chapter 6
Cultures of Ovarian Surface Epithelium from women with and without a hereditary
predisposition to develop female adnexal carcinoma. OSE was harvested from
women with and without a hereditary determined risk on female adnexal
carcinomas. Culture properties, morphology and the expression of epithelial,
mesothelial and fibroblastmarkers were studied. No differences in morphology,
proliferation potential and expression of the above mentioned markers were
identified. Keratins 7/8 expression was one of the studied epithelial markers.
In our study it is observed, that only when cultures are initially 100% keratins 7
and 8 positive, cultures remain epithelial in culture. In all other cases loss of
epithelial character is observed, most probably due to contamination by fibroblasts.
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Chapter 7
BRCA1 and p53 protein expression in cultured Ovarian Surface Epithelial cells
derived from women with and without a BRCA1 germline mutation. Previous studies
from other groups show differences in phenotype of OSE derived from women
with and without a hereditary predisposition to develop female adnexal carcinomas.
However, an explanation on protein expression level is as yet not available.
We studied the expression of BRCA1 and p53 proteins with immunocytochemistry
and western-blot techniques. With these methods, no difference could be detected
in the expression of either protein in OSE from women with and without a BRCA1
germline mutation.
Conclusion and discussion
The studies described in this thesis indicate that intra-abdominal malignancies
related to a hereditary determined high risk for female adnexal tumours are
(mainly) of the serous histotype. The observations: 1) that (pre)neoplasias do mainly
arise in the Fallopian tube and not in the ovary 2) that those few (pre)neoplastic
lesions that do arise in the ovary occur in inclusion cysts lined by cells with the same
morphology as cells found in the Fallopian tube, let us to postulate that not OSE, but
the Tubal inner Surface Epithelium (TSE) is the tissue of origin of serous tumours.
We showed, that TSE easily exfoliates. Since during each ovulation the Fallopian
tube moves over the ovarian surface, it is reasonable to believe, that
[(pre)malignant] TSE can exfoliate on the ovarian surface and into an ovarian
stigma. This theory does not challenge the "incessant ovulation" theory, since it is
realistic to believe that during each ovulation the chance of TSE inclusion in the
ovarian stroma increases. The exfoliation theory is also supported by the
observation that in both women with and without a predisposition on female
adnexal cancer, Fallopian tube obliteration decreases the risk on serous intra-
peritoneal tumours in these women.
Finally, future research to study the exfoliation theory is proposed. 1) Dysplastic
lesions could be subject to molecular biological research 2) molecular comparison
of primary ovarian and Fallopian tube carcinoma and 3) transformation of TSE
with oncogenes and inactivation of tumorsuppressor genes can give information
on (serous) tubal oncogenesis.
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Samenvatting
Dit proefschrift belicht het ontstaan van het ovariumcarcinoom (eierstokkanker).
Jaarlijks wordt deze aandoening bij ongeveer 1500 Nederlandse vrouwen ontdekt.
In de meeste gevallen is dan reeds sprake van een vergevorderd stadium van de
ziekte, waardoor de 5 jaarsoverleving maar 30% is. Een bijkomend nadeel van
het ontdekken van de ziekte in een laat stadium is, dat zeer weinig bekend is over
het vroegste stadium en daarmee het ontstaan van ovarium carcinoom.
In 1994 en 1995 werden respectievelijk de BReast CAncer 1 en BReast CAncer 2
genen gelokaliseerd. Vrouwen met een (overgeërfde) mutatie in een van deze
genen hebben tot 40% kans om in hun leven ovariumcarcinoom te ontwikkelen.
Eén strategie, om bij deze vrouwen de kans op ovarium carcinoom te verkleinen,
is het verwijderen van zowel eierstokken als de eileiders. Onderzoek aan deze
profylactisch verwijderde adnexa kan inzicht verschaffen in het ontstaan van
het ovariumcarcinoom, omdat in deze weefsels met hoog risico op kanker
voorloperstadia daarvan verwacht kunnen worden.
Hoofdstuk 2
Intraperitoneale sereuze adenocarcinomen: de drie hypotheses aangaande de etiologie
kritisch belicht. Uit de literatuur, die over het ontstaan van ovariumkanker gaat,
komen 2 theorieën naar voren aangaande de oncogenese van ovariumcarcinoom,
in het bijzonder over de cellen van oorsprong. In dit artikel postuleren wij een derde
theorie. 
De eerste hypothese gaat ervan uit, dat de laag mesotheelcellen welke over het
ovarium gelegen is, het ovariumoppervlakte-epitheel (OOE), de cellen van
oorsprong vormt. Volgens dit model raken simpele ovarium mesotheelcellen na
een ovulatie eerst ingesloten in het ovariumstroma, om vervolgens metaplastisch te
veranderen, meestal in de richting van tuba-epitheel (sereuze cellen). Deze cellen
kunnen vervolgens dysplasie of maligne ontaarding vertonen. 
Ten tweede wordt het zgn. secundaire Mülleriaanse systeem als voorloper genoemd.
Dit systeem bestaat uit overblijfselen van de embryonale buizen van Müller, welke
normaal de endocervix (binnenste deel van de baarmoeder mond), het endometrium
(bekleding van de baarmoeder binnenkant) en de tuba Fallopii (= eileiders) vormen,
maar waarvan het craniale (bovenste) deel niet geheel in regressie gaat gedurende
de embryogenese. Deze delen vormen in het volwassen leven het, dus uit aberrante
cellen gevormde, secundaire Mülleriaanse systeem. Het idee is, dat deze Mülleriaanse
cellen in alle daaruit voortkomende weefsels (tuba Fallopii, endometrium en
endocervix) kunnen differentiëren om vervolgens tot (pre)maligniteiten te kunnen
verworden.
Naast deze theorieën uit de literatuur postuleerden wij nog een derde mogelijkheid
voor het ontstaan van het sereuze ovarium carcinoom. Gedurende het proces van
ovulatie schuift het fimbrieële deel van de tuba Fallopii over het ovarium oppervlak.
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Hierbij raken tubaire cellen los en raken ingesloten in het ovarium stroma.
Na inclusie kunnen hieruit (pre)maligne cellen ontstaan.
Hoofdstuk 3
Histopathologische karakteristieken van BRCA1- en BRCA2-geassocieerde
adnextumoren en peritoneaalcelcarcinomen. Om inzicht te verkrijgen in welk soort
intraperitoneale tumoren wordt gevonden bij vrouwen met een hereditair hoog
risico, is een inventarisatie gemaakt van tumoren ontstaan in vrouwen en
familieleden, die gezien worden op onze polikliniek familiaire tumoren. In 42
families met een BRCA1 of BRCA2 mutatie werden in totaal 62 mutatiedraagsters
met intraperitoneale maligniteiten beschreven. Vergeleken met een referentiegroep,
verkregen via de Nederlandse Kanker Registratie, komen sereuze tumoren veel
vaker voor in de hereditaire groep. Voorts werd in die gevallen de diagnose primair
tubacarcinoom drie maal vaker gesteld dan in de normale populatie.
Hoofdstuk 4
Dysplastische veranderingen in profylactisch verwijderde tubae Fallopii van
vrouwen met een predispositie voor het ontstaan van ovariumcarcinoom.
Het vóórkomen van (pre)neoplastische laesies in tubae Fallopii van vrouwen met
en zonder een hoog risico op adnextumoren werd bestudeerd. Voorts werd de
expressie van celcyclus- en differentiatieafhankelijke eiwitten bestudeerd. In 50%
van de tubae Fallopii afkomstig van vrouwen met een hereditair verhoogd risico
op adnextumoren werden dysplastische afwijkingen gevonden, tegen geen
afwijkingen in de controlegroep. Voorts was de expressie van de proliferatie- en
differentiatiegerelateerde eiwitten Ki67, p21 en p27 verhoogd in de hereditaire groep
wanneer deze werd vergeleken met de controlegroep. 
Hoofdstuk 5
Expressie van differentiatie- en proliferatiegerelateerde eiwitten in profylactisch
verwijderde ovaria van vrouwen met een hereditaire predispositie voor
adnextumoren. Het vóórkomen van (pre)neoplastische laesies in ovaria van vrouwen
met en zonder een hoog risico op adnextumoren werd bestudeerd. Voorts werd
de expressie van celcyclus- en differentiatieafhankelijke eiwitten bestudeerd.
Een onderscheid werd gemaakt in vóórkomen van laesies op het ovariumoppervlak
en in ovarium inclusiecysten. Noch in ovaria van vrouwen at risk, noch in controle
ovaria werd (pre-)neoplasie gevonden. De expressie van zowel de oestrogeen-
alfareceptor, als p21 en p27 was significant hoger in inclusiecyste epitheel dan in het
ovariumoppervlakte epitheel, van zowel de cases als controles. Voorts was de
expressie van bcl-2 en PR hoger in inclusiecysten van cases invergelijking met
controles.
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Hoofdstuk 6
Kweken van ovariumoppervlakte-epitheel van vrouwen met en zonder een
hereditaire predispositie voor het ontwikkelen van adnextumoren. OOE werd
verkregen van vrouwen met en zonder een hereditair hoog risico op vrouwelijke
adnextumoren. Kweekeigenschappen, morfologie en de expressie van epitheliale-,
mesotheliale- en fibroblastmarkers werden bestudeerd. Er werd geen verschil in
morfologie, proliferatiepotentieel en expressie van bovengenoemde markers
geïdentificeerd. Keratines 7/8 expressie is één van de bestudeerde epitheliale
markers. Uit onze resultaten blijkt, dat alléén wanneer in de eerste passage keratine
7/8 in 100% van alle cellen in kweek tot expressie komt, de kweken 100% epitheliaal
blijven. In alle andere gevallen is er sprake van verlies van het epitheliale karakter
van de kweek. Waarschijnlijk is dit het gevolg van contaminatie met fibroblasten.
Hoofdstuk 7
BRCA1 en p53 eiwitexpressie in humaan ovariumoppervlakte epitheelkweken van
vrouwen met en zonder een BRCA1 genmutatie. Voorgaande onderzoeken van
andere groepen laten een verschil zien in het fenotype van OOE afkomstig van
vrouwen met en zonder een hereditaire predispositie voor adnextumoren. Echter
een verklaring op eiwitexpressieniveau is nog niet gegeven. Daarom bestudeerden we
de expressie van de BRCA1 en p53 eiwitten met behulp van zowel immunocytochemische
als western-blot technieken. Met deze technieken konden we geen verschil
detecteren tussen expressie in OOE afkomstig van vrouwen met en zonder een
BRCA1 genmutatie.
Conclusie en discussie
De studies in dit proefschrift geven aan, dat intra-abdominale maligniteiten, welke
gerelateerd zijn aan een hereditair hoog risico op adnextumoren, (voornamelijk) van
het sereuze subtype zijn. De observaties 1) dat (pre)neoplasieën met name in de tuba
en niet in het ovarium ontstaan en 2) dat de enkele (pre)neoplasie gevonden in het
ovarium ontstaat uit cysten, welke bekleed zijn met cellen met dezelfde morfologie
als cellen, welke worden gevonden in de tuba Fallopii, doet het vermoeden rijzen,
dat niet het OOE, maar het Tubaire -binnen- Oppervlakte Epitheel (TOE)
uiteindelijk het weefsel is, van waaruit sereuze tumoren ontstaan. 
We hebben aangetoond, dat TOE cellen gemakkelijk exfolieëren. Aangezien bij
iedere follikelgroei het fimbriële uiteinde van de tuba over het ovarium oppervlakte
beweegt, is het aannemelijk dat [(pre)maligne] TOE cellen terechtkomen op het
ovariële oppervlak en in een stigma, om uiteindelijk tijdens de wondreparatie
terecht te komen in het ovarium stroma. Deze theorie doet niet af aan de "incessant
ovulation" hypothese, aangezien redelijkerwijs mag worden aangenomen dat bij
iedere extra ovulatie de kans op inclusie van TOE in het ovarium stroma toeneemt.
Daarnaast wordt de exfoliatietheorie ondersteund door de waarnemening dat zowel
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bij vrouwen met als zonder een hereditaire predispositie op vrouwelijke
adnextumoren, het risico van sereuze ovariumcarcinomen afneemt wanneer de tuba
Fallopii geoblitereerd is.
Geëindigd wordt met voorstellen voor vervolgonderzoek, om de exfoliatie theorie te
ondersteunen of te verwerpen, waarbij gedacht moet worden aan moleculair
biologisch onderzoek van 1) dysplastische laesies van de tuba en 2) vergelijking van
primair ovarium- en primair tubacarcinoom. Ten slotte kan transformatie van TOE
met oncogenen of inactivatie van tumorsuppressor genen inzicht verschaffen in
vroege stappen in (sereuze) tubaire oncogenese.
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Jurgen Piek was born on Tuesday oktober 28th 1969 in Arnhem, the Netherlands.
His youth was spent in Doorwerth and Doetinchem. In the last city he went to high school
(first M.A.V.O., thereafter H.A.V.O.). His military duty was fulfilled in 1988 /1989 in
the cities of Venlo and Arnhem. In 1990 he finished high school (V.W.O.). 1990 was the
starting year of his medical education at the University of Amsterdam, which he
interrupted for one year to travel around the world. After his graduation in 1999 he started
as a PhD student at the department of Obstetrics and Gynaecology of the Vrije Universiteit
Medical Center, under the supervision of professor dr. René H.M. Verheijen, professor
dr. Paul J. van Diest and professor dr. Peter Kenemans. The first months he was posted
in New Haven (USA) at the Yale school of Medicine under the supervision of the late
professor dr. B. Kacinski. In Oktober 2003, the author started the training for Obstetrician
and Gynaecologist at the Sint Lucas Andreas hospital in Amsterdam under supervision
of professor Fedde Scheele.
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Jurgen Piek werd geboren op dinsdag 28 oktober 1969 te Arnhem. Gedurende zijn jeugd
woonde hij in Doorwerth en Doetinchem. In de laatst genoemde stad is hij naar de
middelbare school gegaan (eerst M.A.V.O., daarna H.A.V.O. 4 en 5). De militaire
dienstplicht werd in 1988 / 1989 vervuld in Venlo en Arnhem. In 1990 behaalde hij zijn
V.W.O. diploma. In 1990 werd begonnen met de studie geneeskunde aan de universiteit
van Amsterdam. De studie werd gedurende een jaar onderbroken om een wereldreis
te maken. Na het artsexamen, in 1999, begon hij als promovendus op de afdeling
Verloskunde en Gynaecologie van het Vrije Universiteit Medisch Centrum onder
supervisie van professor dr. René H.M. Verheijen, professor dr. Paul J. van Diest en
professor dr. Peter Kenemans. De eerste maanden werkte hij in New Haven (V.S.) aan
het "Yale school of Medicine", onder supervisie van wijlen professor dr. B. Kacinski.
In oktober 2003 startte de auteur zijn opleiding tot Obstetricus en Gynaecoloog aan
het Sint Lucas Andreas ziekenhuis te Amsterdam onder supervisie van professor
dr. Fedde Scheele. 

